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Summary  
Background and aims: Familial hypercholesterolemia (FH) is an inherited, 
metabolic, autosomal dominant disorder. It is characterized by abnormal high total 
cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels. The 
elevated LDL-C levels are caused by mutations in genes affecting the LDL receptor. 
The risks of atherosclerosis and premature cardiovascular disease in patients with FH 
are extremely high due to the poor lipid profile. To date, there is limited experience 
and knowledge about treatment of FH in children, and which requires further 
investigation. This thesis aims to identify effects of monitoring of participants 
involved in previous trials at the Lipid Clinic when they were children. Objective and 
subjective parameters were both evaluated in order to detect factors of importance 
regarding the development and handling of the disease.  
Subjects and methods: This was a systematic clinical exploratory follow-up study, 
which included both retrospective and present measurements. 67 adults (>18 years), 
who had previous participated in clinical trials when they were children, were 
recruited. LDL-C levels were compared in several different groups and subgroups, 
among other between (1) statin users versus non-statin users, (2) gender, (3) 
according to outpatient control routines, (4) medication routines and (5) SmartDiet 
score. We also investigated subjective parameters, among other reasons for poor 
adherence and not taking cholesterol-lowering medication.   
Results: 19 out of 67 participants (28%) did not use statins at time of follow-up. 
Statin users had a significant lower LDL-C level than non-statin users (P <0.001). The 
reduction in LDL-C level among statin users from time of diagnosis to follow-up 
were 50%, but only 12.8% of the statin users achieved the treatment goal of LDL-C 
<2.5 mmol/L. Both genders had a significant reduction in LDL-C and TC levels (P 
<0.001). Females had a greater reduction in LDL-C levels than males (55% and 23%, 
respectively). No explanations for the greater reduction in females were found. There 
was also a significantly lower LDL-C level in participants who had their last 
outpatient control during the last two years before our follow-up (P = 0.044), and a 
numerical lower LDL-C level in those who had an outpatient control every two years 
or more often compared to participants with less frequent outpatient controls (P = 
0.069). 
  
VII  
Conclusion: The great difference in lipid parameters between statin users and non-
statin users illustrates the importance of adequate and continuous medical treatment 
when diagnosed with FH. Further research may be beneficial to explore why females 
had greater reduction in LDL-C level than males in our follow-up. FH is a chronic 
disease, and this present study shows the importance of good outpatient control 
routines in children (<18 years) and young adults.  
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1. Introduction 
 
1.1 Cholesterol  
The main functions of cholesterol in the human body is as a component in the structure and 
function of all human cells, and as a precursor of bile acids, steroid hormones and Vitamin D 
(1). It is therefore of critical importance that all the cells in the human body achieve a 
sufficient supply of cholesterol. A complex series of transport, biosynthetic, and regulatory 
mechanisms has been evolved to meet this need (2-4). 
 
Cholesterol is insoluble in the blood and it is therefore carried in distinct particles, called 
lipoproteins.  
 
1.2 Lipoproteins  
Lipoprotein particles contain both lipid and proteins. They have a hydrophobic core of 
triacylglycerol and cholesterol ester and a hydrophilic outer surface of phospholipid and free 
cholesterol. The lipoprotein packs the hydrophobic cholesterol in the center of the particle, 
while the hydrophilic outer surface makes it soluble and transportable in the bloodstream, thus 
cholesterol can be transported to and from the tissues (2, 3). There are primarily two different 
classes of lipoproteins in the cholesterol metabolism: (1) those containing apolipoprotein B-
100 (ApoB-100) such as very low-density protein (VLDL), VLDL remnants, intermediate-
density lipoproteins (IDL) and low-density lipoproteins (LDL), and (2) those containing 
apolipoprotein A-1 (ApoA-1) such as high-density lipoproteins (HDL). In addition, 
chylomicrons contain ApoB-48. In human blood LDL cholesterol (LDL-C) usually dominates 
with up to 60-70% of the total serum cholesterol (TC), while HDL cholesterol (HDL-C) 
makes up 20-30% (2). TC, HDL-C and LDL-C are commonly measured in clinical practice. 
 
LDL 
LDL is a particle with low density, and transports cholesterol to peripheral tissues in the body.   
The LDL particle has a high concentration of cholesterol and cholesterol esters (2). LDL-C is 
often called “bad cholesterol” because of its strongly atherogenic effect (3). To reduce the 
atherogenic development in blood vessels, LDL-C is the major target of cholesterol-lowering 
therapy.   
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HDL 
HDL is a particle with high density, and transports cholesterol from peripheral tissues to the 
liver. HDL-C is often called “good cholesterol”. Low levels of HDL-C correlates with an 
increased risk of atherosclerosis and coronary heart disease (CHD) events, while high levels 
of HDL-C  have shown protective effects (3).  
 
Lipoprotein (a)                                                                                                            
Lipoprotein (a) (Lp(a)) is an altered form of LDL that contains the ApoB-100 portion of LDL 
linked to ApoA-1. Lp(a) and a LDL particle are nearly identical in structure. Increased levels 
of Lp(a) are associated with higher risk of coronary and cerebrovascular disease, independent 
of TC and LDL-C levels (1). The mechanism whereby Lp(a) may be particularly atherogenic 
is through its binding and transportation of phospholipids (5).  
 
1.3 Apolipoproteins  
Apolipoproteins are proteins that bind lipids to form lipoprotein, and thereby transports lipids 
in serum (6). 
 
The LDL particle includes a single apolipoprotein, called ApoB-100. ApoB-100 is the major 
apolipoprotein of all atherogenic lipoproteins, such as LDL, VLDL and intermediate-density 
lipoproteins (IDL). High levels of total serum ApoB-100 is associated with coronary 
atherosclerosis and CHD events, and is proposed as an alternative to elevated levels of LDL-C 
as risk factor (3, 6).  
 
ApoA-1 is the major protein component of HDL-C and it is an important contributor to the 
removal of cholesterol and fats from the blood, and thereby preventing atheroma. It is usually 
low when HDL is reduced, and a low ApoA-1 is associated with increased risk for CHD, but 
not independently of low HDL (1, 3, 4, 6). 
 
ApoB-100 and ApoA-1 have opposite effects on atherogenic risk, and the ratio between the 
two values, ApoB-100/ApoA-1, is often measured as a predictor of the risk for CHD (6). Two 
studies, the Swedish AMORIS study and the large case-control INTERHEART study, 
reported that ApoB-100/ApoA-I ratio is a significantly better indicator of CHD than any of 
the conventional cholesterol values (7, 8).  
  
3  
 
1.4 Cholesterol- and lipoprotein metabolism                                                                          
The human body obtains the cholesterol both exogenously and endogenously. Dietary 
cholesterol is absorbed in the gut, primarily in duodenum and jejunum. When it passes the 
enterocytes, the cholesterol is transported in the bloodstream to the liver packed in 
chylomicrons. The chylomicrons are rich in triglycerides, have a hydrophilic outer surface 
and are therefore able to be transported in the bloodstream. The body itself also synthesizes 
cholesterol, mainly in the liver, but also from gut and the central nervous system, by 3-
hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. HMG-CoA reductase is the 
rate limiting step in the cholesterol biosynthesis and catalyzes the precursor to cholesterol. 
From the liver, cholesterol and triglycerides (TG) are secreted into the bloodstream as VLDL 
and converted to LDL in the circulation by lipoprotein lipase. LDL further transports the 
cholesterol to peripheral tissues in the body. The uptake of cholesterol in the human cells is 
mediated by LDL receptors (LDLR) (2, 9).   
 
The LDLR is a transmembrane protein and is present in almost all tissues. It controls the 
cholesterol homeostasis by several complex mechanisms. These processes include synthesis 
of the receptor in endoplasmic reticulum, migration of the receptor protein to the cell surface, 
binding of the LDLR to plasma LDL via ApoB-100 etc. (6).  
 
HDL removes excess cholesterol from tissues and facilitates the transport to the liver for 
degradation and/or excretion. This process is called reverse cholesterol transport. Cholesterol 
is further absorbed into the liver in two different ways: (1) either directly uptake from HDL 
via the hepatic class B scavenger receptors, or (2) via hepatic LDLR where the HDL particles 
in advance are transformed into LDL and VLDL. Cholesterol is excreted in the bile, both as 
free cholesterol and as bile acids (2, 3, 9). 
 
High blood cholesterol levels and/or various defects in the cholesterol metabolism may lead to 
lipid accumulation and atherosclerosis.  
 
 
  
4  
 
 
 
 
 
 
 
Figure 1. Lipoprotein metabolism. Adapted from Nature review genetics (10). 
 
1.5 Atherosclerosis  
Intimal thickening and lipid accumulation are the key processes in atherosclerosis (11). 
Circulation of LDL particles may initiate the atherosclerotic process by penetrating into the 
arterial wall. When LDL is passing the sub endothelial space of the arterial wall, it is modified 
in many different ways (6). Modified LDL in the arterial wall recruits phagocytic white blood 
cells, monocytes, which stimulates an inflammatory response and results in accumulation of 
plaque. Atherosclerotic plaques have three principal components: (1) cells, (2) extra cellular 
matrix (ECM) and (3) intracellular and extracellular lipids. The major cells involved in the 
atherosclerotic process are smooth muscle cells, macrophages and T cells. The ECM includes 
collagen, elastic fibers and proteoglycans (12).  
When the monocytes reach the tissue they are differentiated to macrophages which ingest 
oxidized cholesterol and become foam cells and fatty streaks. The fatty streaks are the first 
grossly visible atherosclerotic lesions (6, 12). They are further developed and converted into 
fibrous atherosclerotic plaques, followed by smooth muscle formatting and collagen 
deposition, illustrated in figure 2 (6).  
Accumulation of plaque leads to narrowing and loss of elasticity in the blood vessel wall, and 
are very susceptible to rupture which can lead to acute coronary syndrome (6).  
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In addition to elevated circulating LDL-C ( >4.2 mmol/L) and decreased HDL-C ( <1.0 
mmol/L) there are many other risk factors for atherosclerosis, including cigarette smoking, 
elevated systolic blood pressure (BP) (>140 mm Hg) and diabetes (6).  
 
 
 
 
 
 
 
Figure 2. Inflammation and atherosclerosis. Adapted from Stronk et al (13).  
 
1.6 Ischemic Heart Disease 
Ischemic heart disease (IHD) is a generic term for a group of syndromes resulting from 
myocardial ischemia. Ischemia occurs primarily due to reduction in coronary blood flow 
caused by obstructive atherosclerotic disease. IHD is also frequently called coronary artery 
disease (CAD). CAD is one of the leading causes of death and disability worldwide (11, 14, 
15). In 2011 the most frequent of death causes was IHD, reflecting 11.2% of all deaths (15). 
The basic clinical syndromes of IHD are categorized in four groups, angina pectoris (stable or 
unstable), acute myocardial infarction (MI), chronic IHD (progressive heart failure) and 
sudden cardiac death (SCD). Unstable angina, acute MI and SCD are the three catastrophic 
manifestations of IHD, and have the generic term acute coronary syndrome (11). 
IHD is often caused by a combination of preexisting atherosclerotic obstruction of coronary 
arteries and new superimposed thrombosis and/or vasospasm. The initiating event to acute 
coronary syndrome is typically disruption of a plaque due to rupture, fissuring or ulceration of 
plaques and/or hemorrhage into the core of plaques (6, 11).  
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1.7 Familial Hypercholesterolemia                                                                                            
1.7.1 Definition FH                                                                                                          
Familial hypercholesterolemia (FH) is an inherited, metabolic, autosomal dominant disorder 
characterized by abnormally high LDL-C levels (16, 17). The condition can either be 
heterozygous familial hypercholesterolemia (HeFH) which is caused by inheritance of a 
defective gene from one parent, or homozygous familial hypercholesterolemia (HoFH) which 
is caused by inheritance of a defective gene from both parents (18).  
Subjects with HoFH have an extremely high risk for atherosclerosis and if untreated most 
individuals will experience IHD in childhood or adolescence. HoFH is a much more severe 
clinical disorder than HeFH (15, 19).  
 
Elevated LDL-C levels in HeFH is caused by defects in at least one of the many different 
genes that code for proteins that affects the normal control of lipoprotein metabolism (20). 
The most common (85-90%) is heterozygous loss of function mutations in LDLR gene, 
located on chromosome 19p13.1-13.3. Other heterozygous mutations are (1) mutations in the 
ApoB-100 gene which impair the LDLR binding domain of ApoB-100 (located on 
chromosome 2p23-24), and (2) gain-of-function mutations in proprotein convertase 
subtilisin/kexin type 9 (PCSK9) which gives a new abnormal function (located on 
chromosome 1p32) (17).  
 
1200 different mutations in LDLR have been described, affecting different steps in the LDLR 
biogenesis (21). It results in a dysfunctional LDLR on the cell surface of the hepatocytes. The 
LDLR on the hepatocytes are required for uptake of LDL particles from the circulation to the 
liver, and thus inactivation and degradation of cholesterol in the body (17). A dysfunctional 
LDLR will make the liver unable to absorb sufficient amounts of LDL-C from the 
bloodstream, and LDL-C levels will be elevated (21).  
 
Defects in genes of ApoB-100 and PCSK9 represent about 5-10% of the FH cases (17). 
Mutations in the ApoB-100 gene region, that encodes the LDLR binding domain, reduce the 
binding affinity for the LDL particles to the LDLR and the removal of LDL-C from the 
circulation (22). FH caused by a mutation in the ApoB-100 gene region is apparently less 
severe than FH caused by mutations in LDLR gene (17). PCSK9 is a serine protease that 
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regulates the degradation of the LDLR, and consequently plays an important role in regulating 
the cholesterol into the cells. Circulating PCSK9 binds the LDLR on the cell surface and then 
incorporates with the LDLR. Mutations in PCSK9 lead to a gain-of-function phenomenon, 
and a higher rate of LDLR degradation (23). Mutations in PCSK9 is the least common of the 
three mentioned (17). Individuals with loss-of-function mutations in PCSK9 have reduced 
plasma levels of LDL-C and are therefore protected from CHD. These findings have validated 
PCSK9 as a therapeutic target and suggested new approaches for the treatment and prevention 
of CHD (23).  
 
The life-threatening effects of both HeFH and HoFH are related to the resulting elevation in 
plasma LDL-C, with consequent cholesterol retention in the arterial wall and foam cell 
formation within the intima of arteries. This may further lead to an occlusive atherosclerosis 
(21).   
 
1.7.2 Prevalence 
HeFH is quite common with a prevalence of 1 per 300-500 in many Western countries, while 
HoFH is a less frequent disease with an estimated prevalence of 1 per 1 million (17, 21). To 
estimate the incidence of FH is hard, partly because FH is not attributed an independent code 
in the World Health Organization International Classification of Diseases and partly because 
FH is an underdiagnosed disease (21). 
Although FH occurs in all populations, some ethnic groups are disproportionately impacted, 
where there are founder effects and relatively isolated populations. These include people of 
Lebanese, French Canadian, South African and Ashkenazi Jewish descent. In these 
populations FH may be found as frequently as 1 in every 80-100 people (24, 25).  
Earlier studies have found 1:1 relationship in definite and probable FH in men and women of 
age below 60, while there is a higher prevalence of FH in women at age 60 plus. This 
suggests that a higher number of men FH suffer death of premature cardiovascular diseases 
(CVD) than women (21).  
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1.7.3 Criteria of FH  
Table 1. The Dutch Lipid Clinic Network criteria for diagnosis of HeFH in adults. Adapted 
from Nordestgaard (21).  
Criteria  Points  
Family history  
First-degree relative with known premature ** CHD or first-degree relative with 
known LDL-C >95th percentile by age and gender for country  
First-degree relative with tendon xanthoms and/or corneal arcus or child(ren) 
<18 years with LDL-C >95th percentile by age and gender for country  
                                                              
1 
 
 
2  
Clinical history  
Subject has premature ** CVD  
Subject has premature **  cerebral or peripheral vascular disease  
 
2 
1 
Physical examination  
Tendon xanthoma  
Corneal arcus in a person <45 years  
 
6 
4 
Biochemical results  
LDL-C >8.5 mmol/L  
LDL-C 6.5 – 8.4 mmol/L  
LDL-C 5.0 – 6.4 mmol/L  
LDL-C 4.0 – 4.9 mmol/L 
 
8 
5 
3 
1 
Molecular genetic testing (DNA analysis)  
Causative mutation shown in the LDLR, ApoB-100 or PCSK9 genes  
 
8 
* If the subjects scores > 8 points a “definite FH” diagnosis can be made,  if the subject scores 6-8 points a 
probable diagnosis can be made and if the subject scores 3-5 point a possible diagnosis can be made.  
** Premature: Men: <55 years, women: <60 years 
 
A variety of approaches have been developed for diagnosing FH. A frequently used tool is the 
Dutch Lipid Clinic Network Criteria (table 1). Diagnosis of FH in adults is based on five 
criteria: (1) family history, (2) clinical history of premature CHD, (3) physical examination 
for xanthomas and corneal arcus, (4) elevated LDL-C measurements over time, (5) and/or a 
causative mutation detected by molecular genetics. If the children have a parent with FH and 
LDL-C >3.5 mmol/L, one should consider whether the child also has FH, as the risk is 
increased (21).  
 
The Dutch Lipid Clinic Network Criteria should not be used in children. The optimal age for 
screening children is between 2 and 10 years, when it is optimal discrimination in cholesterol 
levels in children with or without FH. Screening is made on indication, and not performed on 
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the entire population. The reasonable age for initiating a low-fat diet is 2 years, and statin 
treatment is considered safe above age 8-10. Screening and initiating of treatment in early 
ages are considered beneficial (21). 
 
A Norwegian study investigated 956 subjects with FH or Familial Defective ApoB-100 
(FDB) during a 10 years period. In figure 3 the relationship between TC (mmol/L) levels in 
FH/FDB patients without lipid-lowering therapy is plotted against age. The TC levels are 
increasing with age. It further shows TC years score for subjects who initiated lipid-lowering 
therapy at different decades and achieved a TC level of 5.4 mmol/L. The cholesterol-years 
score correlates with atherosclerosis severity in patients with HeFH (26). This study 
demonstrates the importance of early and adequate treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Cholesterol-years score in FH/FDB heterozygotes. Levels of total serum cholesterol in FH/FDB 
heterozygotes in different age groups before lipid-lowering therapy is started are plotted against age of the 
subjects. Adapted from: “Subjects with molecularly defined familial hypercholesterolemia or familial defective 
ApoB-100 are not being adequately treated” (26).    
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1.7.4 Clinical manifestations of FH  
Most patients have no symptoms of hypercholesterolemia at time of diagnosis (24). The 
biggest difficulty is diagnosing the disorder in the asymptomatic population in order to 
commence early treatment (25).  
Some clinical signs are associated with FH. These signs include xanthomas, xantelasms and 
premature CVD. Xantelasms and xanthomas are masses formed by clusters of macrophages 
and foam cells when they are present in subepithelial connective tissues or skin in tendon 
(11).  
The presence of tendon xanthomas is virtually diagnostic for FH. Tendon xanthomas are most 
easily recognized within the extensor tendons such as in the extensor tendons on the dorsum 
of the hands and the Achilles tendons, where they cause thickenings and irregularities (27). 
Xantelasms are usually characterized by deposition of lipid in the cornea, leading to presenile 
corneal arcus (25). Premature corneal arcus is frequently seen in patients with HeFH. Corneal 
arcus is a lipid-enriched and mostly extracellular deposit which is accumulated in the stroma 
of the peripheral cornea (28). 
 
The characteristic biochemical parameters of FH are elevated TC and LDL-C levels from 
birth. In addition, other lipid and non-lipid parameters are often measured in FH patients. 
HDL-C levels are usually slightly decreased, while levels of TG in plasma are often normal. 
Another lipoprotein abnormality is raised concentrations of Lp(a) (29).  
 
Some patients with FH are diagnosed after a premature cardiovascular incidence. The 
premature CVD mainly occurs because of the accelerated atherosclerosis, resulting from an 
abnormally high LDL-C level (29). 
 
1.7.5. Treatment of FH in children and adults  
Treatment of FH involves drug treatment, dietary guidance and recommendations regarding 
lifestyle parameters. 
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Treatment goals 
Table 2. Recommended LDL-C levels for FH patients. Adapted Nordestgaard (21). 
 
 
 
 
The target goals are the same in HeFH and HoFH. Pediatric guidelines recommend lipid 
lowering drug therapy in children >10 years with LDL-C >4.9 mmol/L, or LDL-C >4.1 
mmol/L if there is family history of premature CVD. It is also recommended if there exist at 
least two risk factors for CVD. Dietary modification should have been be tried without 
satisfactory results before initiating lipid-lowering drug therapy (30, 31).  
 
Dietary and lifestyle recommendations in FH 
Diet recommendations  
Dietary treatment and a healthy lifestyle are recommended to all patients with FH in 
combination with lipid-lowering drug therapy (17). The main objectives of the nutritional 
advices are (1) to reduce the amount of foods and beverages with high cholesterol, saturated 
fat, and trans fat content, (2) to avoid overweight and maintain an ideal body weight, (3) no 
smoking and (4) regular physical activity (21, 32, 33). Achieving these advices may reduce 
the LDL-C levels and the risk of CVD.  
Reduction of LDL-C is the major target of dietary treatment in FH patients. This is mainly 
accomplished by enhancing the activity of LDLR and by depressing liver synthesis of 
cholesterol. Both cholesterol and saturated fat down-regulate the LDLR, inhibit the removal 
of LDL-C from the bloodstream and increase the VLDL hepatic synthesis (32, 34, 35). Hence, 
avoiding foods containing a high level of cholesterol and saturated fat is essential in the 
dietary treatment of FH.  
The major foods that are rich in saturated fats include those of animal origin, such as meat fats 
and dairy fats, and those of vegetable origin, such as coconut, palm kernel, palm oils and 
vegetable shortenings (27). Among the animal fats, the dairy fats are more 
hypercholesterolemic than the meat fats, due to its higher content of cholesterol-raising fatty 
 Recommended LDL-C  
Children  <3.5 mmol/L 
Adults  <2.5 mmol/L 
Adults with CHD or diabetes  <1.8 mmol/L 
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acids. The tropic oils (i.e. coconut, palm, and palm kernel oils) have higher content of 
saturated fatty acids than other vegetable oils (6).  
Trans-fatty acids should be completely avoided as these are shown to increase LDL-C levels 
(6). The primary sources of trans-fatty acids are partially hydrogenated unsaturated fatty acids 
used to prepare certain commercial foods, such as fried and baked products (35).  
Unsaturated fats are favorable compared to saturated fats (35). Unsaturated fatty acids, 
typically present in fish and vegetables, lower LDL-C levels when they are exchanged for 
saturated fatty acids in the diet. Hence, unsaturated fats may contribute to a healthier lipid 
profile (27). There are also low fat versions of certain products containing less fat (35).  
An intake of approximately 2g/d of stanols or sterols has shown an LDL-C level reduction of 
about 10%. Enriching foods with stanols or sterols reduce intestinal absorption of cholesterol, 
and consequently lower serum cholesterol levels (36, 37).  
According to National Cholesterol Education Program higher intake of soluble fiber (5-10 
g/d) and soy protein produce stepwise reductions in LDL-C levels (1). 
Patients with FH should be counseled in how the diet impacts their lipid values and risk of 
severe outcomes, and which dietary recommendations to follow. The recommendations 
include (17, 35) :  
Table 3. Diet recommendations  
Recommendations How to meet the recommendations 
Reduced intake of saturated fats and cholesterol Total fat 25-35% of energy intake  
 Saturated fatty acids < 7% of energy intake  
 Dietary cholesterol <200 mg/d 
Use of plant stanol or sterol esters 2 g/d 
Use of soluble fiber 10-20 g/d  
 
Even though diet therapy is well implemented in the treatment of FH, very few randomized 
controlled trials have been conducted on subjects with FH regarding diet. A Cochrane review 
on 11 randomized trials was published in 2010. The participants had various diets: (1) reduced 
total fat intake, (2) reduced intake of saturated fat, (3) reduced intake of cholesterol and (4) 
diet with increased amount of carbohydrates. It summarized that no conclusions could be 
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made about the effectiveness of cholesterol-lowering diet in patients with FH, due to lack of 
long-term trials with parallel group design. However, they found a significant lowering of 
plasma cholesterol when using plant sterols and/or stanols supplements (38). Several studies 
have investigated the TC and LDL-C lowering effects of using margarine or mayonnaise 
containing plant sterols and stanols. They found positive effects, and a maximal efficacy was 
achieved with an intake of about 2 g/d (39, 40).  
 A research team did two studies on healthy adults with hyperlipidemia. They investigated the 
effects of a dietary portfolio of cholesterol-lowering foods. Foods high in plant sterols, soy 
protein, viscous fibers and almonds were used in the studies. The LDL-C reduction was 
28.6% and 12.8%, respectively, both significant (41, 42). 
Although the effects of dietary intervention in treatment of FH are ambigous, there are 
defined diet recommendations for FH patients to follow. 
 
Lifestyle recommendations  
Physical activity  
Regular physical activity (fast walking for 30 minutes five days a week) is one of the lifestyle 
advices of primary prevention of CHD (43).  
Long-term observational studies investigating the benefits of exercise concluded with a 
significantly reduced risk of CHD in those who exercised regularly (44). 
 
Cigarette smoking  
American Heart Association strongly recommends eliminating use and exposure to all 
tobacco products (35). Cigarette smoking has been established as a powerful contributor to 
risk for CHD and other forms of CVD (1). Quit smoking has shown a risk reduction of >20% 
of CVD (6).  
 
FH and statins  
Statins are first choice treatment for all patients with FH (45). Early diagnostic and 
cholesterol-lowering treatment, primarily with statins, is essential for preventing premature 
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CHD. With satisfying statin treatment, studies have shown that  subjects no longer have a risk 
of MI significantly different from that of the general population (45, 46). 
Statins inhibit the enzyme HMG-CoA reductase in the liver and other tissues. Hence, statins 
reduces the synthesis of intracellular cholesterol in the liver. It causes induction of LDLR on 
the cell surface to hepatocytes. Increased number of LDLR further increases uptake and 
metabolism of cholesterol in the liver, and consequently decreases concentration of 
circulating TC, LDL-C and ApoB-100 levels (3, 27, 47).  
 
A long-term cohort study investigated the lipid-lowering effects of two of the most used 
statins in FH patients. It found a reduction in LDL-C of 44% when initiating a Simvastatin 
mean dose of 33 mg, and a reduction in LDL-C of 49% when initiating a mean dose of 49 mg 
of Atorvastatin. It further showed a risk reduction of 76% for CHD compared to untreated FH 
patients (45).  
 
Statin treatment in children 
In Norway, statins are recommended as treatment in children with FH from the age of 8-10 
years. Several studies have found reduced levels of TC, LDL-C and ApoB-100, and increased 
levels of HDL-C and ApoA-1, with use of statins in children. In addition, no harmful effects 
have been identified so far. However, long-term side effects can not be excluded due to lack 
of systematic long-term studies (48, 49).  
 
FH and other medication 
Other medication than statins may also be used if the patient is resistant to statin treatment, 
have side effects of statins, if the treatment goal is hard to reach etc.  
Non-statin lipid-lowering drugs act through different mechanisms than statins, e.g. inhibit bile 
acid or cholesterol absorption. They act synergistic with statins. Used in combination, the 
LDL-C reduction may further increase. Ezetimibe, a cholesterol-absorption inhibitor, can be 
used in a combination with statin for further LDL-C lowering. Even in some HeFH patients a 
combination of high-dose statins and Ezetimibe is not enough to reduce LDL-C levels 
adequate. In this case, bile acids sequestrate and/or niacin can be further added (18).   
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1.8 Why this thesis? 
To date, there is limited experience and knowledge about treatment of FH in children. 
Children and adolescents (<18 years) are vulnerable populations where adherence to treatment 
and understanding of the disease and lifestyle is every-day challenges, and the transition to an 
adult life is difficult. FH is a life-long disease, and it has to be properly monitored over 
several years.  
 
The present master thesis is a systematic follow-up of previous study participants, and aims to 
provide knowledge and insight for future treatment and follow-up of FH patients. 
 
 
 
 
 
 
  
  
16  
2. Aims of the study  
2.1 Study rationale  
This thesis aims to identify effects of follow-up of previous participants involved in drug-
trials and one plant sterol study at the Lipid Clinic, Oslo University Hospital when they were 
children (1999-2008). It examined a number of objective and subjective parameters, such as 
biochemical laboratory values, clinical manifestations and presentations, adherence of 
treatment, diet and lifestyle. Some parameters were, where appropriate, compared to 
recommendations, treatment goals or values at time of diagnosis.  
2.2 Study objective                   
 2.2.1 Specific aims of this thesis  
Research Questions 
i. To describe the following parameters 
- TC 
- LDL-C 
- HDL-C  
- TG  
- Lp(a)  
- BMI 
ii. Objective parameters compared to the treatment goals 
- LDL-C 
iii. Objective parameters in statin users versus non-statin users at follow-up compared 
to time of diagnosis 
- TC 
- LDL-C 
- HDL-C 
- TG 
iv. Differences in objective parameters between genders at time of diagnosis and at 
time of follow-up  
- TC 
- LDL-C 
- ApoA-1, ApoB-100 and ApoB-100/ApoA-1 ratio  
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- HDL-C  
- TG 
- Possible explanations for differences?  
v. Importance of outpatient control routines 
- Association between last outpatient control and LDL-C level? 
- Association between outpatient control frequency and LDL-C level? 
vi. Dietary adherence and association to LDL-C levels  
- Investigation according to SmartDiet questionnaire  
- Adherence  to dietary treatment  
- LDL-C levels in participants with low score versus medium/high score   
vii. Medication adherence   
- Proportion using lipid-lowering drugs  
- Common side effects and consequences  
- Adherence to treatment 
- Reasons for quitting medication and poor adherence 
viii. Subjective experiences  
- Participants` perceptions of their own health 
- Participants` perceptions of being included in a study 
- Participants` fears of CHD events   
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3. Subjects and methods    
This follow-up project was approved by The Regional Committee of Medical Ethics (REK 
Vest), see appendix 1. Written informed consent was obtained from all participants. The data 
collection is based on blood samples, clinical manifestations, individual medical charts, 
SmartDiet questionnaire and a standardized interview. Blood samples were the only 
intervention in this project. Treatment was not initiated as a part of the study, but if there were 
indications for switching or initiating treatment this was implemented afterwards, and did not 
have any impact on the results. We also included measurements from a similar follow-up 
study in 2011, and added it to our original data. 
 
3.1 Study design  
 
3.1.1 Follow-up study  
This was a systematic clinical, exploratory follow-up study. It included both retrospective and 
present measurements.  
 
3.1.2 Substudy 
Gisle Langslet at the Lipid Clinic had the overall responsibility for the project. He applied for 
Chief Physician leave of absence autumn 2013, to investigate FH children who had previously 
participated in clinical trials at the Lipid Clinic. It is planned to use the data in a doctoral 
dissertation, and this master thesis is a subset of this dissertation.  
 
3.2 Subjects 
 
3.2.1 Participants in the follow-up in 2013 
Adults (>18 years) who participated in four clinical trials at the Lipid Clinic, three drug 
studies (study4, study5, study6)  and one plant sterol study (study1), when they were children 
were asked to participate in this follow-up study. This comprised 41 participants in study1 
(1999-2000) and 40 participants in study4, study5 and study6 (2005-2008) (50-53), totaling 
81 participants. 8 persons participated in two of the studies and one person participated in 
three of the studies, leaving 71 individuals to be asked.  
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We have not been able to reach 10 of the 71 participants, three participants were reached by 
telephone once but not answered ever since, and another three participants did not meet for 
planned outpatient controls. The remaining 11 did not want to be included in the follow-up 
study. Two of these stayed in another country, while the other 9 did not have time or did not 
want to participate. Thus, 44 participants were recruited from the four parent studies. Of these 
36 participants were interviewed at the Lipid Clinic, 7 were interviewed by telephone and one 
consented that we used medical chart information. Of the 44 participants interviewed, five did 
not have FH after all. All of them had previously participated in study1 and were excluded 
from our follow-up study.  
 
In addition, a selection of participants not reached or not willing to participate in a similar 
follow-up study in 2011 was requested once again in 2013. Three consented to participate. An 
overview is illustrated in appendix 2. 
 
3.2.2 Participants in the follow-up study in 2011                                                       
The similar follow-up study in 2011 recruited 25 of the 47 previous participants of the two 
statin studies in 2000 and 2001, Akid and Zink (study2 and study3) (54, 55). Data from these 
25 participants were included in our follow-up.  
 
 
 
 
 
 
Figure 4. Timeline of parent studies   
 
 
3.2.3 Participants participated in the follow-up in total  
In total, there were 128 participants in the 6 parent studies of where our participants were 
recruited, shown in table 4.  8 persons participated in two of the parent studies and one person 
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participated in three of the studies, leaving 118 individuals to be asked. 67 of these were 
included in the study, illustrated in figure 5.   
 
For those who participated in more than one of the parent studies the last study participation 
was used as reference.  
 
Table 4. Overview of parent studies  
Trial  Name in this 
follow-up  
Year 
conducted  
Participants  
Plant Sterol  Study1  1999-2000 41 
Akid Study2 2000-2001 25 
Zink  Study3 2000-2001 22 
Welchol Study4 2006-2007 9 
Ezi/Simva Study5 2005-2007 8 
Pluto Study6 2006-2008 23 
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Figure 5. Flowchart of participation  
* Did not have FH  
** Did not have any outpatient control at the Lipid Clinic  
*** Consented us to use information in medical chart  
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3.2.4 Inclusion and exclusion criteria  
An overview of inclusion and exclusion criteria is shown in table 5.  
Enrolled in this study were all subjects previous participated in 6 clinical trials (five drug 
trials and one plant sterol study)  at the Lipid Clinic when they were children (<18years),  
with detected genetic or clinical FH and who signed written informed consent. 
Participants previous participated in clinical trials at the Lipid Clinic when they were children 
(<18 years), but appeared not having FH after all, were excluded from the follow-up study. 
 
Table 5. Inclusion and exclusion criteria  
 
 
3.2.5 Missing values  
In the follow-up study some missing values emerged among other due to incomplete medical 
records, inadequate answers from the participants and the fact that some participants only 
were interviewed by telephone and did not meet for outpatient controls. Missing values were 
not included in the percentage calculation in the result section, except in some analysis where 
including missing values provided a better overall picture. Therefore, almost all percentages 
presented in the results section are “valid percent” based on the participants where the data 
material is available. 
 
3.3 Method 
 
3.3.1 Recruitment  
Persons participating in one or more of the 6 previous clinical trials mentioned above, were 
sent an invitation letter to participate with two copies of informed consent, see appendix 3 
(one copy for the participants themselves and one copy for the researchers), a SmartDiet 
questionnaire (appendix 4)  and a prepaid “return envelope” per post. They were phoned 1-2 
weeks afterwards and asked whether they wanted to participate in the study. If contact was 
not achieved, repeated phone calls were made and a “remainder” letter was sent, see 
Inclusion criteria   Exclusion criteria  
Participated in clinical trial in 1999-2008 at the Lipid Clinic  Participated in clinical trial in 1999-2008, but turned 
out to not have FH Genetic and/or clinical FH 
Signed written consent  
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appendix 5. Potential participants were offered either an outpatient control along with the 
interview, or interview by telephone. If blood tests had not been performed for the last 6 
months or a new treatment regimen was initiated, a new blood test was offered and a 
laboratory requisition was sent.  
 
3.3.2 Biochemical parameters  
At follow-up 
If there were more than 6 months since the last blood sampling with lipid status was taken, 
participants were asked to give a blood test to make ordinary blood analysis at monitoring of 
individuals with FH: lipid status (TC, HDL-C, LDL- C, TG, Lp(a), ApoA-1 and ApoB-100), 
liver-, (ASAT and ALAT) kidney-, and thyroid tests, glucose status and muscle enzyme (CK). 
ApoB-100/ApoA-1 ratio was calculated from the collected blood samples. The participants 
were also asked for a new blood test if the treatment regimen was changed or if earlier blood 
samples did not contain any relevant results. The participants received a requisition in order to 
take a blood test, and the samples were conducted either locally or on the Lipid Clinic. Most 
of the blood tests were analyzed at the laboratory at Oslo University Hospital (OUS), 
Rikshospitalet, but could also have been drawn locally.  
 
Standard procedures for patients not to eat or drink during the past 10 hours before the blood 
sampling were recommended (56). 
 
Laboratory parameters at diagnosis  
Biochemical parameters at diagnosis were collected from medical chart. The oldest values 
which existed in the medical chart were used. All values for lipid parameters such as TC, 
LDL-C, HDL-C and TG existed at diagnosis. In cases were LDL-C levels were missing and 
values for TC and HDL-C existed, Friedwalds formula was used to calculate the LDL-C 
levels.   
 
Lp(a) 
Values for Lp(a) were obtained from medical chart at anytime from time of diagnosis to 
follow-up in 59 participants. Usually there are small changes in Lp(a) values during lifetime. 
Hence, we decided only to use one value for each participant and not to compare Lp(a) values 
at different times.  
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3.3.3 Outpatient control 
All participants enrolled in the follow-up were invited to an outpatient control with Chief 
Physician Gisle Langslet at the Lipid Clinic. The outpatient control included an assessment of 
the laboratory blood samples taken prior to the outpatient control, an assessment of the 
adherence of treatment, potential adverse effects of treatment regime since last outpatient 
control, as well as heart rate measurements and BP recordings.    
 
When assessing frequency of outpatient controls, we included those participants at the Lipid 
Clinic or analogous institutions. If the participants had their first outpatient control 
somewhere outside the Lipid Clinic, the participants themselves reported time from the 
previous parent study participation to first outpatient control. As the Lipid Clinic do not have 
access to records outside Oslo University Hospital, some sporadic controls may have occurred 
at the general practitioner or other institutions without being included in this follow-up.  
 
3.3.4 BP and pulse measurements  
BP and heart rate were measured by Gisle Langslet in all participants who met up at the Lipid 
Clinic. It was measured using Welch Allyn 5300, automated blood pressure device (57). 
Measurements were conducted in the same manner in all participants. It was measured in a 
seated position after 5 minutes of rest, usually on the right arm. 
 
No participants used anti-hypertensive medication, which could have influenced the 
measurements.  
 
3.3.5 The interview 
The interview collected information about age, gender, lipid values, illnesses in the past and 
drug use, possible side effects, information about treatment, outpatient control routines since 
participation in drug trials etc. They were also asked about their experience of having FH and 
how they would evaluate treatment and the outpatient controls they have received. The 
questions used in the interview are shown in appendix 6.  
 
Interviews for previous participants in study2 and study3 (n = 25) were made in the summer 
months in 2011 by a medical student at the University of Oslo. Interviews for previous 
participants in study1, study4, study5 and study6, including three participants in study2 and 
study3 (n=42) were made by the master student in autumn 2013/January 2014. Questions 
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about treatment and side effects of treatment were asked by a Gisle Langslet, Chef Physician 
at the Lipid Clinic.  
 
3.3.6 Anthropometric measurements 
Body weight and height were measured by the master student of all participants who met at 
the Lipid Clinic. Measurements were performed in a similar manner in all participants. 
Among those who had an outpatient control at the Lipid Clinic, we both have self-reported 
and measured body weight and height, while among those who were interviewed by telephone 
we only have self-reported body weight and height.  
 
Body weight was measured on an electronic body weight measurement apparatus called 
SOEHNLE S20, 2763. It was controlled and calibrated last time 14.06.2013 by the Norwegian 
Metrology Service. The patients were weighed without jackets and shoes, and stood in the 
center of the platform and looking straight ahead. Bodyweight was recorded to the nearest 0.1 
kilogram.  
 
Heights of the patients were measured with a manual height measurement scale of the brand 
Seca 222, attached to the wall. The measurements were made with the head in the Frankfurt 
plane, feet flat and with heels almost together, knees straight, heels buttocks, and shoulder 
blades in contact with the vertical surface of the wall (56).  
 
Measured and self-reported weight and height were used to calculate body mass index (BMI) 
with the formula BMI = weight (kg)/height (m)2 (56). 
 
3.3.7 Collection of dietary data 
Information about patients` diet and lifestyle were obtained using SmartDiet, a questionnaire 
with 26 questions developed by the Lipid Clinic, Oslo University Hospital, Rikshospitalet, 
shown in appendix 4. 
 
The questionnaire consists of 21 questions about diet, where 14 of these made the basis of the 
total score. Each of the 14 scoring questions has three response categories for quality and 
specification of the quantity of the most commonly used foods. However, the quantity is not 
accurately recorded. Scores from each questionnaire were summarized. The maximum score 
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the subjects could achieve was 41 points. A total score of <27 is regarded as a low score, and 
indicates several improvements towards a more heart-friendly diet and lifestyle. A total score 
of 28-35 is a medium score, and the participants may obtain benefits of changing diet and 
lifestyle. A total score of >36 indicates a healthy diet. 
 
The 21 questions concern the amount and frequency of average intake of foods of (1) "milk 
and yoghurt", (2) "cream, sour cream etc.", (3) "use of cheese", (4) “cold cuts”, (5) "meat for 
dinner", (6) "fish spread", (7) "fish for dinner",  (8) "mayonnaise, remoulade and caviar", (9) 
"butter or margarine on bread", (10) "plant sterols", (11) "use of fats in food preparation", (12) 
"bread, crackers and other grain products",  (13) "vegetables, fruits and berries", (14) "sweet 
topping and sweet drinks", (15) "chocolate, snacks, cakes, biscuits etc.", (16) "legumes", (17) 
"potato, rice and pasta", (18) "nuts, almonds, etc.", (19) "coffee", (20) "alcohol" and (21) 
“eggs.  
 
The questionnaire also comprises five questions regarding lifestyle parameters: (1) “meal 
pattern”, (2) “height, weight and waist circumference”, (3) “smoking/chew tobacco”, (4) 
“physical activity” and (5) “dietary supplements”.  
  
The form is particularly appropriate in the treatment and prevention of CVD and it has 
previously been validated against 7-day dietary records (58, 59).  
 
Calculating the SmartDiet scores  
In those participants who attended the Lipid Clinic the Chef Physician calculated the 
SmartDiet score manually. To verify the responses, the physician and the participants, went 
through the questionnaire together. The SmartDiet scores in the participants interviewed by 
telephone, who sent their responses by post, were calculated by the master student.  
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3.4 Statistical analysis 
 
3.4.1 Preparation of data to be used in SPSS  
The master student considered, coded and filled out information regarding variables of date of 
birth, age at diagnosis, age at parent study start, age at this follow-up, age when started 
cholesterol-lowering medication, history of cholesterol-lowering medication, biochemical 
values, SmartDiet scores and all subjective responses from the interview, in the statistical 
program SPSS. The information was gathered from the medical records, data from the parent 
studies, blood samples and the participants themselves.   
 
3.4.2 Processing of data  
All statistical analyses were performed using SPSS version 20.0 statistical package for 
Windows (SPSS, Inc., Chicago, Illinois, USA).  
 
The level of statistical significance was set to P <0.05 (2-sided). However, some of the results 
which were not statistically significant may be of clinical importance. This is further 
evaluated in the discussion section. 
 
3.4.3 Presentation of data   
Categorical variables  
The results are presented as frequencies (%) for categorical variables. Categorical variables in 
the current study were outpatient control routines, LDL-C subgroups, BMI subgroups, lipid 
deposits, statin treatment, adherence and side effects of treatment, some of the lifestyle 
parameters, and most of the subjective parameters.  
 
Differences between females and males in frequency of forgetting medication were tested 
with Chi-square-test for Independence. The results are illustrated in a 2 by 2 table. We used 
the value in the row of Continuity correction, which is recommended for 2 by 2 tables (60).  
 
Continuous variables  
To assess whether the continuous variables were normally distributed, Histograms and 
Normal Q-Q plots were evaluated for each variable. Most variables were not normally 
distributed, except all lipid parameters at time of diagnosis, TC at follow-up, and age at time 
of diagnosis, parent study start and follow-up.  
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The continuous data are presented as mean ± SD if the data were normally distributed and as 
median and range (min-max) if the data did not meet the assumptions for normal distribution. 
Differences between continuous data are tested with an Independent Sample T-test when 
normal distribution, and Mann Whitney U test when no normal distribution.   
 
Wilcoxon Signed Rank Test was used to compare lipid parameters at time of diagnosis and at 
follow-up, both when stratified for statin/non-statin users and females/males. The results were 
presented in median differences and p-values.  
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4. Results   
 
4.1 Overview of the study population  
Study population characteristics are summarized in table 6. The final sample consisted of 67 
participants, 29 females and 38 males. Average age at diagnosis was 8.1 (± 3.6) years. The 
average age of the participants in this follow-up was 25 (± 3.0) years, with a range from 19-30 
years.  
 
64 participants were verified by genetic testing. Only three were not genetic tested, but 
diagnosed clinically. 21 different mutations in the LDLR gene were found. The four most 
common mutations, FH-Elverum, C210G, FH-Svartor and FH-Gujerat, occurred in 41 
(61.3%) of the subjects. 
 
9 (13.4%) participants had parents with CHD and 39 (58.2%) had parents or grandparents 
with CHD.  
 
Table 6. Age of the study population  
Characteristics  Female Male Total 
n 1 29 (43.3%) 38 (56.7%) 67 (100 %) 
Age at diagnosis (y) (SD)  7.7 (2.8) 8.5 (4.2) 8.1 (3.6) 
Min-max  3.0-14 1.0-17 1.0-17 
Age at parent study-start (y) (SD) 14 (2.4) 14(1.9) 14 (2.1) 
Min-max 8.2-18 9.9-17 8.2-18 
Age at this follow-up study (y) (SD) 25 (2.6) 24 (3.1) 25 (3.0) 
Min-max 21-30 19-30 19-30 
Data are given as mean and (SD) or number of participants and (%) 
1 n indicates number of individuals (%) 
 
 
An overview of participation in the parent studies among the subjects in our follow-up is 
shown in appendix 7. Most subjects had participated in one previous parent study 59 
(88.1%), while 7 (10.5%) had participated in two previous studies and one participant (1.5%) 
had participated in three previous clinical trials at the Lipid Clinic. Shown in appendix 8, 
more than 70% of the study population was included in the parent studies because their 
parents decided, and participants agreed. One participant (1.5%) was included against its will. 
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Main reasons for participation were the thought of better treatment and monitoring of the 
disease (54.5%), scientific reasons (16.7%), and both of these.  
 
A great majority (90.8%) of the participants found it positive to have been included in the 
study. Approximately two third reported close monitoring, including dietary advices, as the 
most common positive responses. Approximately 10% of the participants reported that they 
had negative experiences of being involved in the study among other due to discomfort during 
blood sample drawing (appendix 8). 
 
4.2 Outpatient control routines  
Outpatient control routines after participation in the parent study are shown in table 7a. There 
were no significant differences in outpatient control frequency the past 10 years between 
females and males (P = 1.0). After participation in parent studies almost all subjects (94.0%) 
had their first outpatient control at the Lipid Clinic, and as many as 58 (86.6%) have had 
every outpatient control at the Lipid Clinic. 46 (68.7%) participants had their first outpatient 
control within two years after the parent studies, while in three (4.5%) participants it took 
more than five years before the first outpatient control.   
 
50 (74.6%) subjects have been to outpatient control more often than every second year the 
past 10 years, while 7 (10.5%) subjects have been to outpatient control less than every third 
year.  
 
The median number of years since last outpatient control was 1.5 (0.0-6.5) years (Table7b). 
No significant differences were found in females and males (P = 0.79). Median years since 
ended the parent studies to participation in this current follow-up were 10 years. 
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Table 7a. Outpatient control routines  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are given in n (%) 
1 n indicates number of individuals  
* N/A values are included in the analysis due to the great number of participants in this group 
** The participants who were at outpatient control every second year are in this category   
N/A = not applicable  
  
 
Table 7b. Outpatient control routines in years  
Characteristics  n 1 Years 
Years since last outpatient control 61 1.5 
Min-max  0.0-6.5 
Years since ended study to participation in follow-up 
              Min-max  
67 10 
5.4-14 
Data are given as median (min-max) 
1 n indicates number of individuals   
Characteristics n 1 (%) 
First outpatient control after parent study participation  
Lipid Clinic 63 (94.0%) 
General practitioner 3 (4.5%) 
Another place 1 (1.5%) 
Changed place for outpatient control after the parent study  
No 58 (86.6%) 
Yes 9 (13.4%) 
If changed, what is the reason  
N/A* 58 (86.6%) 
More practical with local outpatient control 5 (7.5%) 
Have not been followed up at LK/too long to wait for outpatient control 2 (3.0%) 
Do not know  2 (3.0%) 
Years before outpatient control after participation in the parent study  
<1 year 13 (19.4%) 
>1 - <2 years 33 (49.3%) 
>2 - <3 years 18 (26.9%) 
>3 - <5 years 0 (0.0%) 
>5 years 3 (4.5%) 
No follow-up  
Frequency of outpatient control the past 10 years  
<1 year intervals 13 (19.4%) 
>1 - <2 years intervals ** 37 (55.2%) 
>2 - <3 years intervals 10 (14.9%) 
>3 - <5 years intervals 5 (7.5%) 
>5 years intervals 2 (3.0%) 
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4.3 Biochemical parameters  
An overview of lipid parameters at time of diagnosis and at follow-up is shown in table 8a.  
 
Median TC level at diagnosis and follow-up in statin users was 8.5 mmol/L and 5.1 mmol/L, 
respectively, a significant reduction from time of diagnosis to follow-up (P <0.001) of 40%. 
In non-statin users median TC level at diagnosis and at follow-up was 8.4 mmol/L and 7.5 
mmol/L, respectively, a non-significant reduction (P = 0.10). In statin users, median LDL-C 
level at diagnosis was 6.6 mmol/L and 3.3 mmol/L at follow-up. This was a significant 
reduction (P <0.001) of 50%. In non-statin users’ median LDL-C levels at diagnosis and at 
follow-up were 6.8 mmol/L and 5.8 mmol/L, respectively. The reduction was not significant 
(P = 0.55). 
 
We also found a significant difference between median LDL-C level in statin-users vs. non-
statin users of 2.5 mmol/L (P <0.001). Although the median LDL-C level is lower in statin 
users than in non-statin users, the treatment goal of LDL-C <2.5 mmol/L is not achieved (21).  
 
The reduction in females and males in TC level was 43% and 24%, respectively, P <0.001 
(table 8b). In LDL-C level the reduction in females and males was 55% and 23%, 
respectively (P <0.001)  
 
The differences between genders are illustrated in table 8b. Females had significantly higher 
(P = 0.016) TC level at diagnosis than males. This was also applicable in LDL-C levels at 
diagnosis were woman had a significantly higher (P<0.001) LDL-C level than men (7.5 
mmol/L vs. 6.1 mmol/L). However, this difference has reversed at follow-up were women had 
a numerical lower TC and LDL-C level than men. Median TC level in females was 5.4 
mmol/L versus 6.1 mmol/L in males. The difference was 0.7 mmol/L, which was not 
significant (P = 0.24). The median LDL-C value was 3.4 mmol/L in females, while the 
median value among males was 4.7 mmol/L, a difference of 1.3 mmol/L. The difference was 
not statistically significant (P = 0.064).  
 
The values for HDL-C and TG for females and males are within the reference range of 
medical department of Rikshospitalet University Hospital at the time of diagnosis and follow-
up (61).  
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In total, the lipid profile is more beneficial at follow-up than at time of diagnosis.  
 
The median TC and LDL-C level at follow-up for the study population in total are illustrated 
in table 8c. The values were 5.7 mmol/L and 4.0 mmol/L, respectively.  
 
Table 8a. Lipid levels at diagnosis and follow-up  
Data are given in median (min-max) and reduction in % 
1 n indicates number of individuals  
2 Wilcoxon Signed Rank Test, comparison of lipid parameters at time of diagnosis versus at follow-up,  
statistically significant when P <0.05. 
* Used statins at follow-up 
** Did not use statins at follow-up 
*** Reduction in LDL-C (%) from time of diagnosis to follow-up 
**** Wilcoxon Sign Rank Test, statistically significant reduction P <0.001. 
TC = total cholesterol, LDL-C = low-density cholesterol, HDL-C = high-density cholesterol, TG = triglycerides 
Two blood (n = 2) samples are missing at follow-up 
 
 
 
 
 
 
 
 
 
 
 
 
 
 At diagnosis  At follow-up  P 2 
 Statin use * Non-statin use ** Statin use * Non-statin use ** Statin use * Non-statin use ** 
n 1 48 19 47 18   
TC (mmol/L) 8.5 8.4 5.1 7.5 <0.001 0.10 
Min-max 5.5-12 6.6-10 3.6-8.5 6.0-12 - - 
Reduction *** - - (-40%) **** (-11%) - - 
LDL-C (mmol/L) 6.6 6.8 3.3 5.8 <0.001 0.55 
Min-max 4.0-10 5.0-8.5 2.0-6.8 4.0-9.8 - - 
Reduction *** - - (-50%) **** (-15%) - - 
HDL-C (mmol/L) 1.3 1.3 1.4 1.3 0.021 0.94 
Min-max 0.7-2.0 0.8-2.3 0.8-2.5 0.8-2.2 - - 
TG (mmol/L) 0.75 0.76 0.70 0.90 0.23 0.05 
Min-max  0.1-2.9 0.4-1.8 0.4-2.3 0.6-1.9 - - 
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     Table 8b. Differences in lipid parameters between females and males  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                    Data are given as median (min-max) and reduction (%) 
                              1 Median differences between females and males at time of diagnosis  
                             2 Mann-Whitney U Test, differences between genders, statistically significance when P <0.05 
                             * Reduction in % from time of diagnosis to follow-up in females and males  
                           ** Wilcoxon Sign Rank Test, statistically significant reduction, P <0.001.  
                 TC = total cholesterol, LDL-C = low-density cholesterol, HDL-C = high-density cholesterol, TG = triglycerides 
 At diagnosis , 
female 
At diagnosis, 
male 
Median  
differences 1 
 P 2 At follow-up , 
female 
At follow-up, 
male 
Median 
differences 1 
P 2 
n 29 38   27 38   
TC (mmol/L) 9.4 8.0 1.4 0.016 5.4 6.1 0.70 0.24 
Reduction * - - - - (-43%) ** (-24%) ** - - 
Min-max 6.5-12 5.5-11 - - 3.9-9.5 3.6-12 - - 
LDL-C (mmol/L) 7.5 6.1 1.4 0.001 3.4 4.7 1.3 0.064 
Reduction * - - - - (-55%) ** (-23%) ** - - 
Min-max 4.8-10 4.0-8.3 - - 2.0-7.4 2.0-9.8 - - 
HDL-C (mmol/L) 1.3 1.2 0.10 0.53 1.5 1.2 0.3 <0.001 
Min-max 0.7-2.3 0.8-2.0 - - 1.0-2.5 0.8-1.8 - - 
TG  (mmol/L) 0.82 0.69 0.13 0.040 0.70 0.90 0.2 0.070 
Min-max 0.3-2.9 0.1-1.8 - - 0.4-2.3 0.4-2.0 - - 
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Table 8c. TC and LDL-C levels at follow-up in the total study population  
 
 
 
 
 
 
Data are given as median (min-max) 
1 n indicates number of participants  
 
LDL-C subgroups, stratified in statin users (n=47) and non-statin users (n=18), based on the 
LDL-C level at time of follow-up are shown in table 9. 6 (12.8%) of the current statin users 
achieved the treatment goal of LDL-C <2.5 mmol/L, 23 (48.9%) of the statin users had a 
LDL-C level between 2.5 mmol/L and 3.5 mmol/L. None (0.0%) of the non-statin users had a 
LDL-C level of <3.5mmol/L. 11 (23.4%) of the statin users, and as much as 16 (88.9%) of the 
non-statin users, had a LDL-C level above 4.5 mmol/L.  
 
 Table 9. LDL-C subgroups  
 
 
 
 
 
 
 
 
 
Data are given in n (%) 
1 n indicates number of individuals 
2 Cumulative percent <4.5 mmol/L, valid percent >4.5 mmol/L 
LDL-C = low-density cholesterol  
 
As shown in table 10, the median values of ApoA-1 and ApoB-100 at follow-up were within 
the reference range for both males and females, though in the upper layer in ApoB-100 for 
males (61). Females had a higher ApoA-1 level (P = 0.002) and a lower ApoB-100 level (P = 
0.050) and ApoB-100/ApoA-1 ratio (P = 0.001) than males. The values of ApoA-1 and 
ApoB-100 at time of diagnosis were not included in this follow-up.  
 
  
 At follow-up 2 
n 1 65 
TC (mmol/L) 5.7 
Min-max 3.6-12 
LDL-C (mmol/L) 4.0 
Min -max 2.0-9.8 
LDL-C  n (%) 2 
Statin users 
n (%) 
Non-statin users 
n 1 47 18 
LDL-C <2.5 mmol/L  6 (12.8%) 0 (0.0%) 
LDL-C <3.5 mmol/L 29 (61.7%) 0 (0.0%) 
LDL-C <4.5 mmol/L 36 (76.6%) 2 (11.1%) 
LDL-C >4.5 mmol/L 11 (23.4%) 16 (88.9%) 
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Table 10. ApoA-1 and ApoB-100 levels at follow-up  
Data are given as median and min-max values  
1 n indicates number of subjects 
2 Mann-Whitney U Test, statistically significant when P <0.05.  
* Normal range:  Female: 1, 1–2, 3 g/L, Male: 1, 0–2, 0 g/L 
** Normal range: 0, 5–1, 3 g/L 
ApoA-1 = Apolipoprotein A-1, ApoB-100 = Apolipoprotein B-100, ApoA-1/ApoB-100 = Apoliprotein A-1/B-
100   
 
 
Shown In table 11, the median level of Lp(a) were 269 mmol/L.  
 
There were no significant differences in Lp(a) between genders (P = 0.077). 15 (25.4%) of the 
participants had a Lp(a) value <100 mg/L, 28 (47.5%) had a Lp(a) value >300mg/L, while 12 
(28.8%) of the participants had a Lp(a) in the range of 500 – 999 mgl/L and five (8.5%) of the 
participants had a Lp(a) value >1000 mg/L.  
 
There is no significant difference in Lp(a) levels according to CHD history in parents and/or 
grandparents (P = 0.67) between the participants, neither when Lp(a) >300 mg/L (P = 0.77), 
nor when Lp(a)  >500mg/L (P = 1.0), data not shown.  
 
Table 11. Lp(a) levels at anytime  
Characteristics  Total 
n 1 59 
Lp(a) at any time (mg/L) 269 
Min-max 14.0-3360 
Data are given as median (min-max) 
1 n indicates number of individuals 
Lp(a) = Lipoprotein (a) 
 
 
The median values of laboratory parameters such as ASAT, ALAT, CK, glucose and HbA1c 
are generally within the reference range. One non-statin user had moderately elevated CK, 
Characteristics  At follow-up, female At follow-up, male At follow-up, total P 2 
n 1 26 38 64  
ApoA-1 (g/L) *  1.5 1.3 1.4 0.002 
Min- max  1.1-2.0 0.9-1.8 0.9-2.0  
ApoB-100 (g/L )** 1.0 1.3 1.2 0.050 
Min-max 0.6-1.8 0.5-2.3 0.5-2.3  
ApoB-100/ApoA1  0.67 1.0 0.85 0.001 
Min-max 0.3-1.4 0.4-2.3 0.3-2.3  
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while another non-statin user had slightly elevated CK levels. One participant had slightly 
elevated ASAT. Another two participants had slightly elevated ALAT (61). 
 
4.4 LDL-C level according to outpatient control frequency, years since last 
outpatient control and family history of CVD 
Median LDL-C level of those followed up every second year or more often the last 10 years 
was lower (3.6 mmol/L) than the LDL-C levels of those followed up less frequently than 
every two years (4.9 mmol/L). However, the difference was not significant, P = 0.069 (table 
12a). 
 
A significant (P = 0.044) lower median LDL-C level were discovered in those who had been 
to outpatient control two years or less before the interview (3.8 mmol/L), compared to the 
participants who have been to last outpatient control more than two years before the interview 
(5.0 mmol/L), illustrated in table 12b.  
 
Table 12a. LDL-C levels according to outpatient control frequency  
Characteristics  Outpatient control frequency * P 2 
 Every two years or 
more often 
Less than every 
two years 
 
n 1  48 17  
LDL-C levels (mmol/L) at follow-up  3.6  (2.0-7.5) 4.9  (2.7-9.8) 0.069 
Data are given as median (min-max) 
1 n indicates number of individuals 
1 Mann-Whitney U Test, statistically significance when P <0.05 
* The past 10 years  
 
 
Table 12b. LDL-C levels according to years since last outpatient control 
Characteristics  Years since last consultation  P  2 
 Two years or less More than two years  
n 1 41 19  
LDL-C levels (mmol/L)at follow-up  3.8 (2.0-7.4) 5.0 (2.6-9.8) 0.044 
Data are given as median (min-max) 
1 n indicates number of individuals 
2 Mann-Whitney U Test, statistically significant when P <0.05 
LDL-C = low-density lipoprotein cholesterol  
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LDL-C level according to family history of CVD in parents and grandparents is shown in 
table 13. Participants having parents or grandparents with CVD events, had no significantly 
higher LDL-C level (4.2 mmol/L) than the participants not having parents or grandparents 
with CVD events (3.8 mmol/L), P = 0.85. 
 
Table 13. LDL-C levels according to family history of CVD 
Characteristics  CVD in parents or grandparents 
No                              Yes 
P 2 
n 1 27 38  
LDL-C levels  at follow-up (mmol/L) 3.8 (2.0-7.5) 4.2 (2.0-9.8) 0.85 
Data are given as median (min-max)  
1 n indicates number of individuals 
2 Mann-Whitney U Test, statistically significant when P <0.05 
LDL-C = low-density lipoprotein cholesterol  
 
4.5 Clinical findings  
Clinical findings in the study population at time of follow-up are illustrated in table 14. The 
participants were within the normal range of BMI both for measured and self-reported values 
(56). Although more than 60% of the study population was within the normal range of BMI of 
18.5-25.0 (self-reported values), slightly less than one third had a BMI above 25, and is per 
definition overweight.  
 
As expected in a young study population, most of the participants had normal BP values 
(93.7%). Only 3 (7.3%) had slightly elevated BP. No one used anti-hypersensitive medication. 
 
Lipid deposits were detected in 6 (9.2%) subjects, while 9 (13.8%) subjects interviewed by 
telephone did not know whether they had lipid deposits or not.  
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Table 14. Physical examination at follow-up 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are given as median (min-max) and n (%) 
1 n indicates number of participants  
2 Data are given in valid percent  
3 High blood pressure = systolic > 140 mmHg or diastolic >90 mmHg  
4 Lipid deposit: Arcus cornea and/or xanthomas, data from medical records.  
BMI = body mass index, kg/m2 (self-reported and measured), BP = blood pressure  
 
4.6 Treatment and side effects   
Shown in table 15a, median number of years the participants had used statins were 6.6 years 
(except blinded study period), with a range from 0 to 17.6 years. Among the participants who 
started treatment, 43 (64.2%) of them started with statins. 
 
19 persons (28.4%) did not use lipid-lowering drugs at the time of follow-up. One person had 
not been given a prescription due to uncertain FH diagnosis. Another person had got a 
prescription, but never started the medication. The remaining 17 had used statins previously. 
When investigating reasons for subjects not using statins, the following factors are listed: side 
effects, poor routines, lack of motivation, running out of prescription and skepticism about 
Characteristics  n 1 Median / n (%) 
Measured BMI  31 23.4 
Min-max  17.8-37.9 
Self-reported BMI 56 23.2 
Min-max  16.3-35.3 
<18.5  2 (3.6%) 2 
18.5-25.0  36 (64.3%) 
>25.0-30.0  12 (21.4%) 
>30.0  6 (10.7%) 
Systolic BP (mmHg) 41 123 
Min-max   102-144 
Diastolic BP (mmHg) 41 72 
Min-max  51-96 
High BP 3 (%)  41  
Yes  3 (7.3%) 2 
No  38 (92.7%) 
Lipid deposit 4 65  
Yes   6 (9.2%) 2 
No  50 (76.9%) 
Do not know   9 (13.8%) 
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using drugs. There were no statistically difference in females and males regarding use of 
statins at follow-up (P = 1.0).  
 
Table 15a. History of medical treatment   
Characteristics  n (%) 
n 1 67 
Age started with cholesterol-lowering drugs (y) 15 
Min-max 5.0-25 
First cholesterol-lowering medication   
Statin 43 (64.2%) 
Resin 22 (32.8%) 
Never used medication  2 (3.0%) 
Statin treatment, years in total 2 (y) 6.6 * 
Min-max  0.0-18 
Use of statin today  
Yes 48 (71.6%) 
No 19 (28.4%) 
If not what is the reason   
N/A  48 
Run out of pills, have not  renewed prescription 4 (21.1%) 3 
Sporadic use, can not remember / forget 4 (21.2%) 
Pregnancy or  lactation 2 (10.5%) 
Side effects  5 (31.6%) 
Skeptical of use of medicine because of side effects 1 (5.3%) 
Uncertain diagnosis 1 (5.3%) 
Have been prescribed, not initiated  1 (5.3%) 
Data are given as median (min-max) and n (%)  
1 n indicates number of individuals.  
2 Except periods with blinded study medication  
3 Data are given in valid percent  
* n=65, two (n=2) have not ever used medication  
N/A = not applicable  
 
 
A significant difference (P = 0.021) were found between current statin users versus non-statin 
users when statistically tested against number of years since last outpatient control, seen in 
table 15b.  
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Table 15b. Association between use of statins and last outpatient control 
 
 
 
 
 
 
Data are given as median (min-max) 
1 n indicates number of individuals 
2 Mann-Whitney U Test, statistically significant when P <0.0 
 
Among those who used medication, 31 (64.6%) used Atorvastatin (Lipitor) and additionally 6 
(12.5%) used Atorvastatin and Ezetimibe (10mg) in combination, table 16. Less commonly 
used statins were Rosuvastatin and Simvastain.  
 
Table 16. Type of medication  
If using medication, type n (%) 1 Drug dose, mg 2 
N/A 19  
Simvastatin 4 (8.3%) 40 
Atorvastatin  31 (64.6%) 40 
Rosuvastatin  5 (10.4%) 40 
Pravastatin + Ezetimibe 1 (2.1%) 40+10 
Atorvastatin + Ezetimibe 6 (12.5%) 60+10 
Rosuvastatin + Ezetimibe  1 (2.1%) 20+10 
Data are given in median and n (valid percent) 
1 n indicates number of individuals  
2 Median dosages (mg/day) 
N/A = not applicable  
 
 
24 (40.7%) participants take their medicine every day, while as much as 17 (28.9%) 
responded to forget the medicine once a week or more often (table 17a). There was no 
difference between the genders in frequency of forgetting to take their medicine (P = 0.88), 
shown in table 17b. The far most common reason for forgetting their medicine was 
irregularities/poor routines (50%).   
 
  
Characteristics        Use of statins P 2 
 Yes No  
n 1 42 19  
Years since last outpatient control  1.4 (0.0-6.5) 2.2 (0.08-5.9) 0.021 
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Table 17a. Adherence to medical treatment  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are given as n (valid percent) 
1 n indicates number of individuals  
N/A = not applicable  
 
 
Table 17b. Adherence to medical treatment among genders  
 
 
 
 
 
 
 
 
Data are given in n (%), n indicates number of participants  
1 Chi-Square Test, statistically significant when P <0.05 
* Of the participants using medication  
** “Yes, periodically” (n = 3) is taken out of the data material for this analysis.  
 
 
More than 35% of the study population has experienced side effects due to lipid lowering 
medication. The gastrointestinal side effects occurred most frequently (n = 12, 46.2%), 
followed by musculoskeletal complaints. 
 
Characteristics  n 1 (%)  
Do you forget to take the medicine?  
N/A 7 
Never  24 (40.7%)   
1-2 times a month 16 (27.1%) 
Once a week 9 (15.3%) 
More often than once a week 8 (13.6%) 
Yes, periodically 2 (3.4%) 
What are the reasons for poor adherence?  
N/A 31 
Irregularities/poor routines 17 (50.0%)   
Traveling 7 (20.6%) 
Run out / missing prescription 1 (2.9%) 
Do not know 1 (2.9%) 
Other 8 (23.5%) 
  Females Males P 1 
Forget medication * 
1-2 times a 
month or never  
19 (73.1 %) 21 (67.7%) 0.88 
Once a week or 
more often ** 
7 (26.9%) 10 (32.3%)  
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Among participants reporting side effects more than two thirds reported that it affected their 
quality of life to some degree. However, there were only three (11.5%) participants where the 
side effects affected the quality of life in a great extent. 
 
Among the study population reporting side effects 19 (73.1 %) changed or stopped using their 
medication, and 7 of them stopped permanently. 
 
Table 18. Side effects of medical treatment  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are given in n (valid percent) 
1 n indicates number of individuals  
N/A = not applicable  
 
 
Characteristics n 1  (%)  
Side effects  
No 39 (58.2%) 
Yes  24 (35.8%) 
Maybe 
Do not  know/  Have not used medication ever 
2 (3.0%) 
2 (3.0%) 
If side effects, which type   
N/A 41 
Gastrointestinal 12 (46.2%) 
Muscle or joint pain 5 (19.2%) 
Headache  1 (3.8%) 
Fatigue  
Gastrointestinal + headache 
0 (0.0%) 
2 (7.7%) 
Gastrointestinal + fatigue 
Muscle pain + headache 
Muscle pain + fatigue 
Other 
1 (3.8%) 
1 (3.8%) 
3 (11.5%) 
1 (3.8%) 
If you ever have had side effects how has it affected your quality of life?   
N/A 41 
Nothing 5 (19.2%) 
A little 18 (69.2%) 
Much  3 (11.5%) 
If side effects, how has it affected your treatment?  
N/A 41 
Not affected  6 (23.1%) 
Slightly affected  1 (3.8%) 
Discontinuation of treatment/change of treatment 19 (73.1%) 
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4.7 Diet and lifestyle  
SmartDiet score was gathered in 64 participants, where the median score was 32.5 points of a 
total maximum score of 41 points. This was in the range of a medium score level.  
 
The median level in total SmartDiet score in females and males was 34.0 and 31.5, 
respectively. However, the difference was not significant (P = 0.075).    
 
The median score for milk and dairy products was high, which means that they had a high 
consume of low-fat dairy products. The same was applicable for intake of meat and meat 
products during a week, while they had a low intake of fish and fish products and therefore a 
lower score. For vegetables and fruits the median score was two out of a maximum of three 
points. Less than one quarter of the participants used omega-3 supplementation and plant 
sterols at follow-up.  
 
Median LDL-C in participants with a medium and high SmartDiet score (n = 56) of >27 was 
3.6 mmol/L compared to 4.9 mmol/L in participants with low SmartDiet score (n = 8) of <27.  
However, the difference was not significant (P = 0.70).  
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Table 19. SmartDiet questionnaire  
Data are given as median and max-min, or n (%) 
1 n indicates number of individuals  
2 High SmartDiet score means a score of 36 points or more 
3 Medium SmartDiet score means a score between 28 and 35 points  
4 Low SmartDiet score means a score of 27 or lower.  
*  Maximum 3 points  
** Maximum 6 points  
*** Used valid percent  
 
 
In table 20, hours of exercising per week are shown. In median the participants used 1.0 hour 
a week training body strength and 2.5 hours on endurances. Within the study population there 
was a great range between the participants; from the participants who did not use any time 
exercising, to one participant who used more than 20 hours a week.  
 
Most of the study population consumed alcohol during a week. Almost 70% consumed 1-7 
units’ alcohol during a week, while a small group of the study population (13.4%) reported 
that they never consumed alcohol.  
 
46 (69.7%) had never used tobacco, only five (7.6%) smoked daily, while 7.6% reported 
themselves as “party-smokers”. The participants who previously had smoked or smoked at 
Characteristics n 1 Median  
Total SmartDiet score at study visit (of maximum 41 points) 64 32.5  
Min-max  19.0-39.0 
High 2  9 (14.1%) * 
Medium 3  47 (73.4%) 
Low 4  8 (12.5%) 
Consumption of cheese on the bread, cooking, on the pizza ect. * 62 2.0  
Consumption of milk and dairy products ** 62 5.0  
Consumption of fish and fish products during one week ** 62 3.5  
Consumption of meat and meat products during one week ** 61 6.0  
Consumption of fruit and vegetables during one week * 62 2.0  
Consumption of bread and cereals during one week * 61 3.0  
Use of omega 3 supplementation (% )*** 64  
Yes  18 (28.1%) 
No  46 (71.9%) 
Use of plant sterols (%) *** 62  
Yes  18 (29.0%) 
No  44 (71.0%) 
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follow-up had in median smoked for approximately 6 years. A greater number used chew 
tobacco, with a total of 18 (26.9%) in the study population. In median they had used “Swedish 
snuff” for almost 5 years.   
 
Table 20. Lifestyle – Physical activity, alcohol consumption and tobacco use  
Characteristics, n=66 Median/ n (%) 
Exercise  
Hours strength, per week 1.0 
Min-max 0.0-7.5 
Hours endurances, per week   2.5 
Min- max  0.0-20 
Alcohol, units per week  
0 9 (13.4%) 
1-7 46 (86.7%) 
8-14 9 (13.4%) 
15 units or more  2 (3.0%) 
Tobacco use  
No/never  46 (69.7%) 
Yes  5 (7.6%) 
“Party smoker”/rarely 2 5 (7.6%) 
Have quitted   10 (15.2%) 
If yes, number of years smoked, (n=19 3) 6.0 
Min-max 0.2-12 
“Swedish snuff” use   
Yes 18 (26.9%) 
No 44 (65.7%) 
Occasionally  1 (1.5%) 
Have quitted  3 (4.5%) 
If yes, number of years used “Swedish snuff” 4.75 
Min-max 0.1-14 
Data is given as median and min-max or n (valid percent) 
1 n indicates number of individuals  
2 Definition “party-smoker”: 1-2 times a week – 1 times a month 
3 The last one does not remember how many years he/she has smoked.  
 
4.8 Subjective evaluations of own health  
There are just as many participants that are satisfied with their cholesterol levels (46%), as 
there are participants that are dissatisfied (46%), illustrated in table 21a.   
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Table 21a. Subjective evaluation of cholesterol levels   
Are you satisfied with your cholesterol values?  n 1(%)  
Agree fully 8 (13.1%) 
Agree partly 20 (32.8%) 
Neither agree or disagree  5 (8.2%) 
Disagree partly 11 (18.0%) 
Disagree fully 17 (27.9%) 
Data are given as n (valid percent) 
1 n indicates number of individuals 
 
More than 27 (40%) of the study population believed that their heath was better than the 
average, shown in table 21b. Almost half of the study population (45.5%) was worried about 
having a CHD event, and 53 (80.3%) of the participants believed that their treatment will 
prevent them from having a CHD event.  
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Table 21b. Subjective evaluation of own health  
Characteristics  n 1 (%) 
How do you consider your health?  
 
Better than average  27 (40.9%) 
Average  34 (51.5%) 
Worse than average  5 (7.6%) 
Are you worried about having a CHD event because of FH?   
Agree fully  6 (9.1%) 
Agree partly  24 (36.4%) 
Neither agree or disagree  7 (10.6%) 
Disagree partly  13 (19.7%) 
Disagree fully  16 (24.2%) 
Do you rust that your treatment will prevent you from having a 
CHD event? 
 
Agree fully   19 (28.8%)  
Agree partly  34 (51.5%) 
Nether agree or disagree 5 (7.6%) 
Disagree partly 5 (7.6%) 
Disagree fully  3 (4.5%) 
Are you afraid that one of your parents who has FH will have a 
CHD event (again)?  
 
 
Agree fully  26 (40.0%) 
Agree partly  16 (24.6%) 
Neither agree or disagree  5 (7.7%) 
Disagree partly  6 (9.2%) 
Disagree fully  12 (18.5%) 
Are you anxious that your children can inherit FH from you?  
Agree fully 20 (30.3%) 
Agree partly  22 (33.8%) 
Neither agree or disagree  5 (7.7%) 
Disagree partly  8 (12.3%) 
Disagree fully  10 (15.4%) 
Data are given in n (valid percent)  
1 n indicates number of individuals  
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5. Discussion  
In this thesis we did a follow-up of participants in 6 randomized clinical trials at the Lipid 
Clinic from 1999 to 2006. It involves cross-sectional measurements and retrospective 
measurements of clinical and biochemical parameters, and current and retrospective 
evaluations by the participants themselves about aspects of their lives with FH since the 
parent studies. 
 
5.1 Discussion of study design, subjects and methods  
No one has, as far as we know, performed this type of follow-up, which include thoroughly 
measurements of both objective and subjective parameters.  
 
Advantages 
The genetic nature of FH necessitates lifelong lifestyle and treatment adherence, and long-
term follow-up is essential. Mean follow-up from end of parent study until this current study 
was 10.3 years. A long-term follow-up study, such as this one, provides information about 
changes in the disease over time, in addition to a cross-sectional picture.    
 
In addition to collecting biochemical parameters and other objective signs, the present study 
obtained the participants’ subjective experiences and perceptions of having FH. Quality of 
life, how a chronic disease has influences on life etc. are questions few other studies have 
investigated. 
 
Another advantage of this study design was the probable health benefit effects for the 
participants. They got to reevaluate their disease, treatment and handling of the disease after 
several years living with FH. They also got the possibility of having an outpatient control and 
obtained information from physicians.  
 
Limitations  
One limitation of this follow-up study is that we did not have a matched control group, neither 
of non-FH participants from the same period or of FH patients not having participated in 
clinical studies. Therefore, we were unable to investigate whether there was a difference 
compared to similar individuals with or without FH, and our results were compared with a 
normal population`s guidelines as well as other similar studies.  
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The parent studies had a total sample size of 118, and we were able to recruit 67 (56.7%). Our 
sample size was small, but comparable to another follow-up study of FH children and 
adolescents (62). FH is relatively rare (1/300-500), and among those having it there is only a 
portion that has been diagnosed. One assumes that one third of a total of 15-20 000 FH 
patients are diagnosed in Norway.  
 
Missing data 
There were variable amounts of missing data in the different analyses. In SmartDiet scores, 
and the biochemical and subjective parameters, there were no or only a few missing data. 
Naturally, for those interviewed per telephone, the clinical findings “measured BMI” and 
“BP” were missing. Information about “lipid deposits” was in some cases collected from the 
medical charts. Although the missing data may have influenced the results to some degree, the 
clinical findings were usually in the normal range and corresponded to the values in the 
general population.   
 
Selection bias  
There is a risk of non-response bias, where those individuals who refused to participate in the 
follow-up were systematically different from those who accepted. “The healthy volunteer 
effect” is a well-known phenomenon, when healthy individuals are more likely to participate 
in a study (63). Among the 118 participants in the previous parent studies, 67 participants 
were included in our follow-up, a response rate of 56.8%. There were different causes why 
the remaining 51 participants did not participate. Among the requested previous participants 
in 2013, 17 were not willing to participate for various reasons, while 10 participants were not 
reached. Data regarding previous participants who not participated in 2011 were missing. 
Probably there is some degree of selection bias, where those not participating in our follow-up 
had higher cholesterol levels, poorer adherence to medical treatment and diet 
recommendations, less frequent follow-up consultations etc. 
 
Information Bias 
Information bias may have occurred due to subjective answers in the interview and/or food 
questionnaire.  
 
Reporting bias is a potential bias in the current follow-up. Under- or over reporting, e.g. when 
completing the SmartDiet questionnaire and responses in the interview to somewhat sensitive 
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questions, can not be excluded (63). Undesirable behaviors with respect to FH may have been 
underreported, for instance intake of saturated fat, alcohol consumption and smoking. Over 
reporting is most likely to have occurred regarding to e.g. physical activity, intake of fish and 
use of dietary supplements, which are examples of factors that contribute to good health. Two 
reviews concluded with a general over reporting of height and underreporting of weight, and 
thereby a lower self-reported BMI (64, 65). We did not make any further controls of the 
provided information, neither in the SmartDiet questionnaire nor in the interview, and can 
therefore not exclude reporting bias.    
 
Observer- or interviewer bias occurs when the interviewers  introduce errors in the 
questionnaire or help the participants, intentionally or not, responding in either directions 
(63). Interviewer’s prior insight of the responders may influence the structure and the manner 
of presentation of the questions, which further may influence the responses (66). To avoid this 
bias we used similar and standardized questions for all study participants, both in 2011 and 
2013. In addition, we strived to make the interviews neutral and objective. This was obtained 
when the same person made similar interviews in the same setting, except for the interviews 
made by telephone.  
 
5.2 Discussion of statistics  
Histograms and QQ-plots were used to evaluate normal distribution for all the parameters.  
 
For overviewing characteristics we used Descriptive statistics and Frequencies statistics. 
Mainly, the results were presented with median and range (min-max) or number of subjects 
(n) and percent (%). We used minimum and maximum levels instead of quartiles because it 
illustrates the whole spectrum of the participant’s values. In cases with normally distributed 
variables, mean ± SD were used. Most variables were not normally distributed and we 
therefore used median and range, as this presentation is more appropriate when the data is 
skewed (60). In most studies mean and SD are used for presentation of the middle value. 
Therefore, our median values are not completely comparable to mean values presented in 
other studies.  
 
We consulted a statistician about whether parametric or non-parametric tests were most 
reasonable to use in our analysis. Despite a relatively large sample size (n = 67) and the fact 
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that e.g. cholesterol levels usually are normally distributed in the general population, many of 
our analysis did not meet the assumptions for normal distribution. A possible explanation may 
be extreme values in patients who are handling the disease improperly. We did not exclude 
extreme values in our study when they are both clinical important and may be numerous in 
some subgroups.   
 
For data not normally distributed we used the non-parametric technique Mann Whitney U test 
to compare different parameters between groups or subgroups (60). This technique takes 
outliers in small sample size into consideration and uses a median as a middle value. This was 
advantageous in many of our analysis. To compare variables from time of diagnosis to time of 
follow-up we used Wilcoxon Signed Rank Test. Non-parametric tests may to a lesser extent 
discover the differences, which further may lead to loss of significant results. However, there 
was only one analysis, the difference in LDL-C levels in outpatient frequency the last 10 
years, which was significant when we used a parametric test (Independent Samples T-Test, P 
= 0.045) and not significant when we used a non-parametric test (Mann Whitney U Test, P = 
0.069). Despite the fact that this result did not become statistically significant, one may 
assume clinical relevance. We could also have transformed the non-parametric data to meet 
the assumptions of the parametric tests. However, in the literature there is a considerable 
disagreement about usage of these techniques (60). 
 
Parametric tests were made to verify data which showed a tendency toward a normal 
distribution. One should use parametric tests instead of non-parametric where it is 
appropriate. This is due to the differences in construction of the tests, and the fact that some 
statistically significant results may disappear when using non-parametric tests on normal 
distributed variables. We used the parametric techniques Independent Samples T-Test and 
Paired Samples T-test to investigate possible loss of statistically significant results when 
using non-parametric tests. However, these results are not included in our study.   
 
When we stratified the study population in gender or other subgroups, there were at some 
occasions few subjects in each group. For instance, when comparing adherence of treatment 
between genders, the group which reported to forget the medication once a week or more 
often consisted of only 7 females and 10 males. Probable significant results may have 
disappeared due to the low sample size. However, the significant values obtained from the 
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small number of subjects in some of our analysis may indicate a strong association between 
the variables.   
 
Bonferroni correction was not made in our analysis. Some significant associations may have 
occurred “by chance” due to multiple comparisons when we performed multiple tests on the 
same data material. This study is exploratory of nature and does not make any hard endpoints, 
and after we conferred with a statistician we decided not to use this correction or any other 
adjustments.   
 
5.3 Discussion of the results 
Subsequently, the principal results will be discussed and put into context of the findings in 
other scientific studies. 
 
5.3.1 Study population  
Our study sample included 67 relatively young participants, with an average age of 25. The 
distribution of gender was not statistically even, with a somewhat higher proportion of males 
(56.7%).  
 
5.3.2 Previous study participation  
The mean age of study start was approximately 14 years. For those who participated in more 
than one study the age of the last study participation were used. This may have influenced the 
mean age. Parents’ decision was the main reason for children participating in the parent 
clinical trials. As the mean age of parent study start was approximately 14 years, it was 
expected that parents’ involvement would be of great importance. Children may not be able to 
cope with the disease themselves, and therefore parents` involvement may be necessary to 
ensure proper handling. FH is a genetic disorder and at least one of the parents and often also 
other family members have the disease. Hence, parents typically possess some knowledge 
about FH in advance, and may be a good resource.  
 
Subjective evaluation about disease and study participation  
Few previous studies have investigated children`s experiences of being involved in clinical 
trials. According to our findings most children had positive experiences of being included in 
the parent clinical trials (90%), and reported to obtain benefits (70%). The positive responses 
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were mainly due to more frequent outpatient controls, including more knowledge about the 
disease. Approximately a quarter of the study population mentioned dietary advices as one of 
the positive experiences. The positive experiences were to some extent correspondingly to the 
reasons for participating, where frequent outpatient controls, better treatment and help with 
science were most common reasons.    
 
A small number of studies have investigated FH-patients` own perceptions and experiences of 
having the disease. One study explored FH specific concerns in children and their parents 
regarding children`s knowledge and experiences of the disease. It found no impaired quality 
of life in these children. However, the results showed poor knowledge about the disease, e.g. 
one-third of the study population thought that FH could be cured (67).  
 
A second study assessed the experiences of guilt and shame in FH patients. They found that 
the study population did not have any guilt about having the disease, but did feel guilt and 
shame in how they managed it (68).   
 
Less than half of the study population reported to be concerned about having a CHD event. 
This finding may reflect lack of experience of disease and/or knowledge, when the risk of 
CHD is significant higher. On the other hand they may have knowledge about the risk, but do 
not let the fear influence their lives. A previous study explored FH patients’ vulnerability to 
CVD. This study concluded additionally that FH patients develop a dynamic and personal 
sense of vulnerability to CVD. They describe situational factors, such as CVD in family 
members or experience of CHD-related symptoms, as an initiator to the dynamic perceived 
vulnerability (69).   
 
Four out of five participants believed that their treatment will prevent them from having a 
CHD event. FH patients with proper treatment and handling, and lipid values within the 
reference range, have no increased risk of CHD compared to the normal population. However, 
an interestingly aspect is the great trust of treatment preventing them from CHD events and, at 
the same time, the poor adherence to treatment. 
  
5.3.3 Outpatient control routines  
Most patients continued to be monitored at the Lipid Clinic after participation in the parent 
studies. It is favorable for monitoring of treatment and measurements that the same clinic 
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performs all the outpatient controls. It is also easier to detect improvements or stagnations of 
the disease. 
 
Our results illustrated the importance of frequent follow-up. Those who had their last 
outpatient control within two years had significant lower LDL-C levels compared to those 
with more than two years since last outpatient control. Although, there may be a selection bias 
that patients who had their last outpatient control within two years are more concerned about 
their disease, which may have contributed to the lower LDL-C level. The difference in LDL-
C levels between the participants who were followed up every two years or more often versus 
the participants followed up less frequently than every two years was not statistically 
significant (P = 0.069). However, a larger sample size would most likely have led to a 
significant difference, and one may assume that more frequent outpatient controls are 
associated with lower LDL-C levels. Nevertheless, it may be of clinical importance.  
 
5.3.4 Biochemical parameters  
Almost half of the study population was satisfied with their cholesterol levels, while there was 
only 9% who achieved a treatment goal of LDL-C <2.5mmol/L. In other words, it is a 
discrepancy in what some participants consider as satisfactory cholesterol levels and the 
treatment goals. Whether the discrepancy is due to lack of knowledge about the treatment 
goals, or the experience that the treatment goals are too hard to achieve, is unknown. A large 
Dutch cross-sectional study investigated why FH patients with a LDL-C level of >2.5 mmol/L 
did not use maximum therapy. They found that the physicians` acceptance of a higher target 
LDL-C level was the main reason (70).  
 
TC and LDL-C   
Due to the large differences in lipid parameters between statin users and non-statin users, we 
chose to stratify data to obtain a more adequate presentation of the study population.  
 
There was a significant (P <0.001) decrease in the TC levels of 40% in statin users from time 
of diagnosis to time of follow-up, but no significant (P = 0.10) decrease were found in non-
statin users. This implicates that early diagnosis and subsequently adequate treatment are 
important for satisfactory TC levels.  
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According to the European guidelines on CVD prevention in clinical practice, the 
recommendations for subjects at high risk for CHD, including FH subjects, is TC <4.5 
mmol/L (71). Although there was a significant improvement in the TC levels, the statin users 
had a median TC level of 5.1 mmol/L, and this subgroup in total did not reach the treatment 
goal. 
 
As expected, regarding LDL-C levels at time of diagnosis and at follow-up, the same pattern 
as for TC levels was observed. In our follow-up, there was a significant (P <0.001) reduction 
in median LDL-C level among statin users of 50%, but no statistically (P = 0.55) difference in 
non-stain users was observed. A comparable follow-up study from the United States found a 
total LDL-C reduction of 43% in statin users, and concluded therefore with significantly 
reduced risk of CVD (62).  
 
According to ESC/EAS guidelines, the recommended treatment goal for LDL-C is 2.5 
mmol/L (21). In our follow-up, the statin users had a median LDL-C level of 3.3 mmol/L at 
follow-up, and only 6 (12.8%) had LDL-C levels according to the treatment goal. Among 
non-statin users there were none who achieved a LDL-C level <3.5 mmol/L. Our finding of a 
low fraction achieving the treatment goal is consistent with results from two other studies, 
were only 21% and 22% achieved the treatment goal. These studies suggested hesitation to 
prescribe the most potent medication, mainly due to the acceptance of higher LDL-C levels 
than the recommendations, or extremely high LDL-C levels at baseline, as probable 
explanations (70, 72). In 2008, National Institute for Health and Clinical Excellence (NICE) 
introduced a new treatment goal; a LDL-C reduction of >50%. In our study, the participants 
who used statins at follow-up had a reduction in LDL-C levels of 50% and are therefore 
achieving the new NICE treatment goal. FH patients often have extremely high LDL-C levels 
before initiation of treatment, and a relatively large proportion who achieved the new NICE 
treatment goal would not achieve a LDL-C level <2.5 mmol/L. Hence, physician using the 
new NICE guidelines may contribute to the low proportion achieving the original treatment 
goal of LDL-C <2.5 mmol/L when they accept higher LDL-C levels.  
 
Females had a numerical lower TC level than males. Despite the lack of significant result (P = 
0.24), the median difference in TC level was 0.70 mmol/L, and one may assume that the 
difference would have been statistically significant if there was a greater number of subjects. 
This was even more prominent for the LDL-C levels, where the difference was 1.3 mmol/L 
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and the P-value was 0.064. To summarize, our follow-up showed lower levels in TC and 
LDL-C in females, but the results were not significant most likely due to a small sample size. 
Although the differences were not statistically significant, it may be of clinical importance. 
 
Why do females have greater reduction in TC and LDL-C levels than males?  
Females had a substantially greater reduction (55%) than males (23%) in LDL-C levels. At 
time of diagnosis they had significantly higher levels of both TC and LDL-C.  This may have 
contributed to the greater reduction. Nevertheless, females have numerical lower TC and 
LDL-C levels than males at follow-up. Another possible explanation for the greater reduction 
from time of diagnosis to follow-up in females is that females are more concerned and 
worried about their own health. However, none of our results indicated a different behavior 
between the genders, neither in the medication adherence (P = 0.88), use of statins at follow-
up (P = 1.0), outpatient control frequency past 10 years (P = 1.0), years since last outpatient 
control (P = 0.80), nor in the SmartDiet score (P = 0.075). On the other hand, there were three 
non-statistically significant values in favor of females. 
 
However, this is an exploratory study and the gender difference in reduction of TC and LDL-
C levels were not investigated in particular.  
 
HDL-C and TG 
In our follow-up we have mainly been focused on TC and LDL-C levels, when FH arises due 
to defects in LDL-C metabolism and LDL-C is the main target for treatment. Nevertheless, 
there are separate recommendations for HDL-C and TG levels. FH patients may have lower 
HDL-C than the normal population, TG is generally the same as for the normal population, 
but it may be elevated for the same reasons as for the general population (29).   
 
In our follow-up the median HDL-C levels in statin and non-statin users were 1.4 mmol/L and 
1.3 mmol/L, respectively. The median levels were 1.5 mmol/L for females and 1.2 mmol/L 
for males, which was within the normal range for both genders (71). Low HDL-C is 
associated with increased risk of CVD  in population studies (73).  
 
According to the European guidelines on CVD prevention in clinical practice, the 
recommended TG levels is <1.7 mmol/L (71). The median TG levels in statin and non-statin 
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users were 0.7 mmol/L and 0.9 mmol/L, respectively, which was within the normal range and 
according to these recommendations.   
 
ApoA-1, ApoB-100 and ApoB-100/ApoA-1  
Females had a higher ApoA-1 than males (P = 0.002). As expected, due to higher LDL-C 
levels in our study and higher normal values, ApoB-100 levels were higher for males than 
females (P = 0.050). The ApoB-100/ApoA-1 in females and males was 0.67 and 1.0, 
respectively, and the difference was statistically significant (P = 0.001). According to this 
prominent difference in ApoB-100/ApoA-1 ratio, one may assume a greater risk for CVD in 
males compared to females in our study population. The large INTERHEART study divided 
the participants into quintiles based on the ApoB-100/ApoA-1 ratio, and concluded with a 
stepwise increased risk of CVD from low to high quintiles. Odds ratio for the highest quintile 
compared to the lowest was 3.87 (8). Similar results were found in the Swedish AMORIS 
study, were they also concluded with a stepwise increased risk ratio (7).   
 
Lp(a) values  
There was a great difference in Lp(a) levels within the two groups of gender and the range 
was huge between low and high values (median levels of 373 mg/L in females, and 162  mg/L 
in males). There was no significant difference between the genders (P = 0.077).  
 
Several studies have investigated Lp(a) levels and risk of CHD. A Danish study, which 
included 9330 females and males from the general population in Copenhagen,  observed a 
stepwise increase in risk of MI with increasing levels of Lp(a), and no threshold value was 
discovered (74). A large meta-analysis with patient records of more than 120 000 patients 
concluded with a continuous, independent and modest association between Lp(a) and risk of 
CHD and stroke (75, 76).  
 
Summary biochemical parameters  
The main findings regarding biochemical parameters in our study were (1) that statin users 
had a better lipid profile in general than non-statin users, and (2) that females had greater 
LDL-C reduction and lower ApoB-100/ApoA-1 ratio than males. One may therefore assume 
that statin users have lower risk for CVD than non-statin users, and that females have lower 
risk for CVD compared to males, based on the biochemical parameters.  
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5.3.5 Clinical findings  
There was almost no difference in self-reported and measured BMI (23.2 and 23.4, 
respectively). This indicates good self-awareness and self-control, and there is no information 
bias for this parameter. Self-reported weight and height are parameters one may assume have 
a great risk of information bias (64, 65). Hence, this finding may strengthened other 
subjective results in our follow-up, when it may reduce the risk of information bias in general. 
As for the general population there are some participants with higher or more extreme BMI 
values. Participants in our follow-up had a lower average BMI than adults (40 years old) in 
the Oslo-area, where the average BMI in females and males are 25.2 and 26.4, respectively 
(77). However, there were no data for BMI in the same group of age as the study population, 
and the results are therefore not completely comparable.  
 
BP increases with age and as expected in a young study population, most of the participants 
had normal BP values (92.7%) at follow-up.  
 
Apart from elevated cholesterol values, clinical signs of FH are relatively uncommon, 
especially in young age. Only 9% of our patients had lipid deposits. A careful anamnesis with 
family history, biochemical tests and/or genetic tests is therefore necessary for the diagnosis 
of FH. 
 
5.3.6 Medical treatment  
Several studies have indicated that use of statins in children is as safe and effective as in 
adults (48, 51, 55, 78). However, the studies are of relatively short duration compared to the 
life-long treatment recommended in FH, but clinical experiences with long-term treatment 
from young age are increasing. In Norway, statins are recommended as cholesterol-lowering 
therapy to children with high cholesterol levels or family history of CHD or CVD from the 
age of 8-10 years (47). Those are the same guidelines which are proposed in a recent review. 
They concluded that statin treatment can be initiated at 8 years of age, when no harmful 
effects are observed. However, a long-term multicenter study with a large study population is 
needed to reveal potential long-term side effects in children (78).  
 
In our study, most participants on statins used Atorvastatin at follow-up, median dose 40 
mg/day. The median dose Simvastatin at follow-up was also 40 mg/day. A randomized, 
double-blinded clinical trial performed on 325 patients with FH concluded that a high-dose 
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(80mg) Atorvastatin produced a larger reduction in LDL-C level (8.0 vs.3.9 mmol/L) than 
conventional dose (40 mg/day) Simvastatin (8.3 vs.4.8 mmol/L). High-dose Atorvastatin also 
produced a significant reduction in carotid intima media thickness compared to an increase 
with Simvastatin (79). Another study which compared high-dose Atorvastatin (80mg) versus 
Simvastatin (40mg/day) concluded that Atorvastatin is the most efficient statin in treatment of 
FH patients, and induces regression of atherosclerosis (80). Due to the more potent effect, 
Atorvastatin is usually preferred instead of Simvastatin at the Lipid Clinic.   
 
19 of 67 (28.4%) participants did not use statins at follow-up. A Dutch cohort study who 
observed more than 2000 patients with FH, found a 76% overall risk reduction for CHD 
among patients with statin treatment relatively no statin treatment. Most of the participants in 
the cohort study (n = 1067) used Simvastatin (mean dose of 33mg), which provided a LDL-C 
reduction of 44%. Another 221 participants used Atorvastatin (mean dose of 49mg) which 
contributed to a reduction of 49% in LDL-C level. During statin treatment the mean TC, 
LDL-C and HDL-C levels in the cohort study were 5.9 mmol/L, 4.0 mmol/L and 1.28 
mmol/L, respectively. These findings indicate the importance of long-term statin-treatment, 
despite of not achieving the treatment goal of LDL-C <2.5mmol/L (45). In addition, a British 
long-term prospective registry study with 3382 participants with FH found a coronary 
mortality reduction of one-third since use of statins in greater extent. It also showed a 
significant reduction in all-cause mortality and fatal cancer (46). This emphasizes the 
importance of taking the cholesterol-lowering medication when having FH.  
 
Side effects of treatment   
Side effects that occurred most frequently among the study population were abdominal 
complaints (46.2%) such as flatulence, constipation, nausea and diarrhea, in addition to 
muscle/joint pain and fatigue. These are side effects specified as usual for statins (47).  
 
A high proportion (n = 19, 73.1%) of the participants who reported side effects discontinued 
or changed the medication. 7 of them stopped the medical treatment permanently, which is 
very unsatisfactory according to LDL-C levels, which is illustrated in the difference between 
current statin users and non-statin users in our follow-up.  
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Adherence  
As much as 60% of the statin users reported that they forget to take their cholesterol-lowering 
medicine 1-2 times a month or more often. The poor adherence to statin therapy is startling 
with respect to the great risk of hazardous disease due to unsatisfactory treated FH. A review 
stated that adherence may be even more challenging in adolescents due to the unique 
development, psychosocial factors and lifestyle issues (81). A standard routine of taking the 
medication is beneficial, and thoroughly education about the importance of adequate and 
continuously treatment may be of great value. However, despite the relatively poor adherence 
in statin users the difference between current statin users and non-statin users is astonishing.  
 
Potential reasons for not taking cholesterol-lowering medication 
Firstly, side effects and poor routines were the main reasons for why participants did not use 
medication at follow-up. Although side effects may occur, they are dose-dependent and may 
disappear or lessen in intensity when the dose is reduced. Patients may also react differently 
to different statins, and switching statin can also be an option. Adequate advice and frequent 
monitoring is necessary to ensure good routines and prevent participants from quitting 
medication.  
 
Secondly, infrequent monitoring may be a potential reason for quitting medication. In our 
follow-up study there was a significant difference in number of years since last outpatient 
control between current statin users and non-statin-users, P = 0.021.  
 
Thirdly, hypercholesterolemia is often an asymptomatic disease, and patients may not 
experience any symptoms. More than 90% of the participants subjective considered their 
health as average or better than average. The lack of experiences and symptoms of the disease 
may further lead to the perception that they do not need their cholesterol-lowering medicine, 
despite the risk of hazardous outcomes. In our study there were more frequently the 
participants` grandparents that had suffered CVD than the parents. This may further lead to a 
greater distance to the disease, and the perception of not having increased risk of disease 
compared to the normal population.  
 
There was only one person who stopped medication due to breast feeding. Statin therapy is 
contraindicated from three months before planned pregnancy, during pregnancy and when 
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breastfeeding (82).  
 
5.3.7 Diet and lifestyle  
Diet and SmartDiet score 
All participants in the parent trials have previously received advices on cholesterol-lowering 
diet at the Lipid Clinic. The SmartDiet questionnaire is the scoring sheet we used to evaluate 
heart-friendly diet and lifestyle status. Diet in FH children and young FH subjects versus non-
FH children and young subjects were investigated in a previous study. Findings in this study 
showed a higher SmartDiet score in FH children than in non-FH participants, and a more 
favorable diet regarding the public recommendations. They also found that FH children had 
healthier food choices than non-FH children, particularly with respect to the most important 
sources for saturated fat. The age group 18-28 years had a median level of 33 (33). In our 
follow-up, with a median SmartDiet score of 32.5, the participants had a “middle score”. 
However, in this high-risk population further improvements may be beneficial, and the 
patients should still be advised and motivated to obtain a better diet and lifestyle.  
 
A limitation of the SmartDiet score is that it does not quantify the intake of the foods. It was 
therefore difficult to compare the scores with the public recommendations. Nevertheless, it 
may be a good tool to identify diet and lifestyle status. It is filled out rapidly by the 
participants, and also time saving for the investigators. The difference in median LDL-C 
levels in participants with SmartDiet score of >27 compared to LDL-C level in participants 
with SmartDiet score of <27 was 1.3 mmol/L. The difference was not significant (P = 0.70). 
We may therefore not conclude with an association between high SmartDiet score and 
beneficial LDL-C levels. However, the difference may be of clinical relevance, and a small 
number of subjects (n = 8) in the group of low SmartDiet score may have contributed to the 
lack of significant results. Other possible explanations are (1) the fact that relatively small 
differences in diet is of limited importance compared to e.g. statin treatment, (2) that the 
SmartDiet scoring sheet has too low sensitivity, (3) information bias or misunderstanding of 
the scoring sheet, or (4) that the participants` diet and lifestyle habits are quite similar.   
 
Smoking 
In our study population there were 7.6% who smoked regularly and 7.6% were party-smokers. 
This was a relatively small proportion compared to the general Norwegian population, where 
around 15% smokes daily and 9% occasionally (83). As mentioned above, smoking is a 
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strong risk factor for atherosclerosis and CVD (6, 84). The Nurses` Health Study (NAHNES) 
found a positive association between the number of cigarettes smoked per day and risk of fatal 
CHD, and increasingly risk with increasingly number of cigarettes. Even 1-4 cigarettes per 
day were associated with a twofold increased risk of fatal CHD (85). As this group already 
has a high risk for CHD, the patients should be tried motivated to eliminate additional risk 
factors such as use of tobacco (86, 87).    
 
Physical activity 
American College of Sports Medicine and the American Heart Association (1995, updated 2007) 
found an inverse association between increasing physical activity and risk of CHD (88). This 
inverse association is also stated in a report published by Word Health Organizations  
 
The participants in our study used in median 1.0 hour on body strength and 2.5 hours on 
endurance per week. The Nordic Recommendations 2012 recommends that “Adults should 
engage in at least 150 minutes of moderate-intensity physical activity throughout the week, or 
engage in at least 75 minutes of vigorous-intensity physical activity throughout the week, or 
engage in an equivalent combination of moderate- and vigorous-intensity activity” (89). In 
median, the participants in our follow-up had a higher physical activity level than suggested in 
the recommendations. However, the range among the participants was great, and some 
participants may obtain benefits of increasing their activity level.  
 
Multiple dietary and lifestyle factors  
Earlier studies have concluded that dietary and lifestyle factors together have a more powerful 
effect on CHD risk than any single factor alone. The great risk reduction among women in the 
Nurses` Health Study and Health Professionals` follow-up study was detected in those who 
did not smoke, were not overweight, maintained a healthful diet, exercised moderately on a 
daily basis, and consumed moderately amounts of alcohol (84). 
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6. Conclusion and clinical implications 
In our follow-up study we have shown that 
 
A. statin users had a significantly lower LDL-C level than non-statin users. Although the 
difference was huge, few statin users achieved the treatment goal of LDL-C <2.5 mmol/L. 
Despite the high risk of hazardous outcomes of severe hypercholesterolemia, 19 of 67 
participants did not use statins at time of follow-up. 
 
B. there was a greater reduction in LDL-C levels from time of diagnosis to follow-up in 
females than in males. None of our analysis found an explanation for the greater reduction. 
There was no difference in (1) medical adherence, (2) use of statins (3) frequency of 
outpatient controls (4) years since last outpatient control or (5) SmartDiet scores. Females had 
also a significantly lower ApoB-100/Apo-A1 ratio than males.  
 
C. participants who more recently had their last outpatient control had a significantly lower 
LDL-C level. There was also a numerical lower LDL-C level among participants with more 
frequent outpatient control. However, the difference was not statistically significant most 
likely due to small sample size, and the result may be of clinical importance.  
 
D. there was no significant association between SmartDiet scores and LDL-C levels.   
 
E. most children had positive experiences of being included in the parent studies and reported 
to obtain benefits. An interestingly aspect was the great trust of treatment preventing them 
from CHD events, and at the same time, the poor adherence. 
  
In conclusion, our findings show the importance of statin treatment to obtain a more 
beneficial LDL-C level. Statin users obtained a considerably reduction in LDL-C level from 
diagnosis to follow-up, and their levels were far lower compared to non-statin users. Adequate 
education about the effect of statin treatment and a thoroughly follow-up of medication 
history may be necessary to ensure maintenance of statin treatment, when poor routines and 
side effects were the main reasons for quitting medication and poor adherence. Females had a 
greater reduction in LDL-C levels and lower ApoB-100/ApoA-1 ratio than males, which may 
suggest a lower risk for CVD. Furthermore, close and frequent follow-up were associated 
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with reduced LDL-C levels, which implicates the importance of regularly contact between FH 
patients and a specialized health center.  
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7. Future perspectives  
This follow-up has generated new knowledge particularly regarding the importance of 
frequent and close outpatient controls, and the participants’ subjective experiences of having 
FH and being included in a study. These are aspects of FH and other chronic diseases where 
limited research exists. 
The present study has shown that a huge proportion of the participants stopped taking their 
cholesterol-lowering medication/statins based on their own decision, and for further treatment 
and monitoring of FH patients at the Lipid Clinic this area will be very important to intercept 
and prevent.  
Moreover, there are generated a basis for further research and hypotheses, among other why 
females have greater reduction in LDL-C levels than males. In this exploratory study we did 
not investigate this gender difference in particular, and welcome future studies to do so.  
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Appendix 2: Flowchart of participants interviewed by the master student 
* Not reached or not willing to participate in 2011  
** Previous participated in study1, but did not have FH after all  
***  Did not meet up for outpatient control at the Lipid Clinic  
**** Consented us to use information from medical chart   
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Appendix 3: Request for participation in the follow-up project  
 
”Langtidsoppfølgning av barn med Familiær 
Hyperkolesterolemi etter deltakelse i kliniske studier” 
 
Bakgrunn og hensikt 
Dette er et spørsmål til deg om å delta i en forskningsstudie for å se hvordan det har gått med 
barn som har deltatt i utprøvinger av kolesterolsenkende medisiner og plantesteroler i Norge. 
 
Hva innebærer studien? 
Studien innebærer et telefonintervju eller at du møter opp ved Lipidklinikken personlig. Det 
vil bli spurt om ”vanlige journalopplysninger” som blant annet vekt, høyde, blodtrykk, 
lipidverdier, allergier, kosthold, tidligere sykdommer, medikamentbruk og eventuelle 
bivirkninger av medikamentene. Du vil også bli spurt om hvordan det er å leve med familiær 
hyperkolesterolemi (FH) og hvordan du vurderer behandlingen og oppfølgingen du har fått. 
Deltakere som ønsker utvidet vurdering vil få tilbud om poliklinisk time/vurdering ved 
Lipidklinikken. Dersom det er mer enn 6 måneder siden du sist målte kolesterolnivået, dersom 
du har endret behandlingsopplegg siden forrige blodprøve, eller dersom tidligere prøver ikke 
inneholder alle blodprøvesvarene vi ser etter, vil du bli spurt om å avgi en blodprøve for å 
måle dette, i tillegg til vanlige sikkerhetsblodprøver.  
 
Mulige fordeler og ulemper 
Ulempe for deltakerne vil være tidsforbruk. Mulige fordeler vil være gjennomgang av 
sykehistorie og eget behandlingsopplegg. 
 
Hva skjer med prøvene og informasjonen om deg? 
Informasjonen som registreres om deg skal kun brukes slik som beskrevet i hensikten med 
studien. Alle opplysningene og prøvene vil bli behandlet uten navn og fødselsnummer eller 
andre direkte gjenkjennende opplysninger. En kode knytter deg til dine opplysninger og 
prøver gjennom en navneliste. Det er kun autorisert personell knyttet til prosjektet som har 
adgang til navnelisten og som kan finne tilbake til deg. Det vil ikke være mulig å identifisere 
deg i resultatene av studien når disse publiseres. 
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Frivillig deltakelse 
Det er frivillig å delta i studien. Du kan når som helst og uten å oppgi noen grunn trekke ditt 
samtykke til å delta i studien. Dette vil ikke få konsekvenser for din videre behandling. 
Dersom du ønsker å delta, må du undertegne samtykkeerklæringen på siste side. Om du nå 
sier ja til å delta, kan du senere trekke tilbake ditt samtykke uten at det påvirker din øvrige 
behandling. Dersom du senere ønsker å trekke deg eller har spørsmål til studien, kan du 
kontakte overlege Gisle Langslet på telefon 23 075 603 eller mobil 90 144 284. 
 
Ytterligere informasjon om studien finnes i kapittel A – utdypende forklaring av hva 
studien innebærer. 
Ytterligere informasjon om biobank, personvern og forsikring finnes i kapittel B – 
Personvern, biobank, økonomi og forsikring.  
 
Samtykkeerklæring følger etter kapittel B.
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Kapittel A- utdypende forklaring av hva studien 
innebærer 
 
Kriterier for deltakelse 
Voksne (>18 år) som tidligere har deltatt i kliniske studier ved Lipidklinikken mens 
de var barn (<18 år) vil få forespørsel om deltakelse per brev og/eller telefon. Totalt 
er dette 85 personer. 
 
Bakgrunnsinformasjon om studien  
Familiær hyperkolesterolemi (FH) er en arvelig, autosomal dominant sykdom hvor 
genfeil fører til redusert antall LDL-reseptorer. Dette fører til høyt kolesterol fra de 
første leveår og åreforkalkninger allerede fra puberteten. Tidlig og livslang 
kolesterolsenkende behandling, hovedsakelig med statiner, forhindrer 
åreforkalkninger og gir omtrent like god livsprognose som normalbefolkningen. 
Lipidklinikken utførte i 1999-2000 en studie med bruk av plantesterolmargarin til 
barn med FH og deltok i flere studier med kolesterolsenkende medisiner i perioden 
1999-2008. I 2011 ble det gjennomført en intervju-undersøkelse av 32 deltakerne i to 
av disse studiene. Vi ønsker nå å etterundersøke deltakerne som ikke ble undersøkt i 
2011 og slå dette sammen til ett forskningsmateriale.    
 
Undersøkelser, blodprøver og annet den inkluderte må gjennom 
Se beskrivelse på side 1 under avsnittet: Hva innebærer studien.   
 
Tidsskjema – hva skjer og når skjer det? 
Intervjuene vil bli gjennomført i løpet av 2013 og 2014.  
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Kapittel B - Personvern, økonomi og forsikring 
 
Personvern 
Opplysninger som registreres om deg er ”vanlige journalopplysninger” som blant 
annet alder, kjønn, vekt, høyde, blodtrykk, lipidverdier, allergier, kosthold, tidligere 
sykdommer og medikamentbruk og eventuelle bivirkninger av medikamentene. Oslo 
Universitetssykehus Rikshospitalet ved administrerende direktør er 
databehandlingsansvarlig. 
 
Rett til innsyn og sletting av opplysninger om deg og sletting av prøver  
Hvis du sier ja til å delta i studien, har du rett til å få innsyn i hvilke opplysninger som 
er registrert om deg. Du har videre rett til å få korrigert eventuelle feil i de 
opplysningene vi har registrert. Dersom du trekker deg fra studien, kan du kreve å få 
slettet innsamlede prøver og opplysninger, med mindre opplysningene allerede er 
inngått i analyser eller brukt i vitenskapelige publikasjoner.  
 
Økonomi 
Prosjektet gjennomføres av Lipidklinikken og det er ingen økonomiske interesser i 
prosjektet. 
 
Forsikring 
Da dette er en intervju-undersøkelse er det ingen forsikring av studiedeltakere. 
Eventuell blodprøvetaking vil være ledd i vanlig poliklinisk oppfølging. 
Blodprøvetaking er forbundet med svært liten risiko, men eventuelle skader vil måtte 
meldes til Norsk Pasientskadeerstatning og dekkes på vanlig måte for poliklinisk 
virksomhet.  
 
Informasjon om utfallet av studien 
Resultatene fra studien vil bli sammenskrevet og forsøkt publisert i et vitenskaplig 
tidsskrift. Et populærvitenskaplig sammendrag vil bli tilsendt deltakere etter 
publisering. 
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Samtykke til deltakelse i studien 
 
Jeg er villig til å delta i studien  
 
 
-------------------------------------------------------------------------------------------------------
--------- 
(Signert av prosjektdeltaker, dato) 
 
------------------------------------------------------------------------------------------------------- 
(Navn med blokkbokstaver) 
 
 
Stedfortredende samtykke når berettiget, enten i tillegg til personen selv eller 
istedenfor 
 
 
------------------------------------------------------------------------------------------------------- 
(Signert av nærstående, dato) 
 
-------------------------------------------------------------------------------------------------------
--------- 
(Navn med blokkbokstaver) 
 
 
 
Jeg bekrefter å ha gitt informasjon om studien 
 
 
------------------------------------------------------------------------------------------------------- 
(Signert, rolle i studien, dato) 
 
------------------------------------------------------------------------------------------------------- 
(Navn med blokkbokstaver) 
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Appendix 4: SmartDiet questionnaire   
  
84  
  
  
85  
Appendix 5: «Reminder-letter» 
 
Kjære FH-pasient, 
 
Vi skriver til deg fordi du har deltatt i en studie for barn og unge med utprøving av 
kolesterolsenkende medisin på Lipidklinikken, og fordi du tidligere har fått en 
forespørsel om å delta i en oppfølgingsstudie etter dette.  
 
Vi har ikke greid å komme i kontakt med deg etter den første forespørselen og vil 
derfor spørre deg pånytt om du vil delta i en slik oppfølging, se vedlagte 
pasientinformasjon.  
 
Som ledd i oppfølgingsstudien vil du også kunne få tilbud om en time til legekontroll 
på Lipidklinikken. Vi har erfaring for at jevnlig oppfølging er av stor betydning for 
behandlingen ved familiær hyperkolesterolemi.  
 
TA KONTAKT 
Hvis du er interessert i å delta ber vi deg ta kontakt med oss.   
 
Kontaktpersoner:                                            
 
Gisle Langslet, lege, Tlf. 23 075 617 
Ida Halvorsen, masterstudent, Tlf. 924 55 393  
 
 
 
Dersom du ikke ønsker å delta i oppfølgingsstudien, ber vi om ditt samtykke til å 
innhente opplysninger fra din fastlege eller behandlende lege om hvilket 
kolesterolnivå du har og hvilken behandling du får for høyt kolesterol. Dette er også 
viktig informasjon for oss, da vi gjerne vil vite hvordan utviklingen har vært hos unge 
FH pasienter. Du må da skrive under på samtykket nedenfor, og returnere det i 
vedlagte returkonvolutt.  
 
SAMTYKKE  
 
Jeg samtykker til at Lipidklinikken kan innhente opplysninger fra min fastlege eller 
behandlende lege om hvilken behandling jeg får for familiær hyperkolesterolemi og 
resultater av blodprøver i forbindelse med behandlingen. 
 
 
Signatur:                                                             Dato:  
-------------------------------------------------------------------------------------------------------
Navn med blokkbokstaver:  
------------------------------------------------------------------------------------------------------- 
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Appendix 6: Questions used in the interview (in Norwegian)  
 
Hvem bestemte at du skulle delta i studien? 
Hva var grunnen til at du/foreldrene dine ønsket å delta i studien? 
Hvor enig eller uenig er du i påstanden "som barn opplevde jeg det som veldig slitsomt å delta i 
studien" 
 Helt enig, Delvis enig, Verken uenig eller enig, Delvis uenig, Helt Uenig 
Hvor enig eller uenig er du i påstanden "nå i ettertid ser jeg på det å ha vært med på studien som noe 
positivt" 
Fikk du noe spesielt ut av studien enten positivt eller negativt som du vil kommentere? 
Fullførte du studien? 
Hvis ikke fullført, hvorfor stoppet du før tiden? 
Hvis fullført, opplevde du noen bivirkninger i løpet av studien? 
Hvor mange år etter studien gikk det før du fikk oppfølgning? 
Hvor mange år etter studien gikk det før du fikk oppfølgning? 
Hvor var det første stedet du  fikk oppfølgning etter studien? 
Har du byttet oppfølgning senere? 
Hvis ja, hvorfor byttet du? 
Hvor mange ganger i året har du vært til oppfølgning av ditt høye kolesterol i de siste ca 10 årene? 
Husker du omtrent hva totalkolesterol har vært (i "snitt") disse 10 årene? 
Husker du omtrent hva LDL har vært (i "snitt") disse 10 årene? 
Husker du omtrent hva HDL har vært (i "snitt") disse 10 årene? 
Husker du omtrent hva triglyserider har vært (i "snitt") disse 10 årene? 
Hvordan tror du kolesterolet har endret seg siden studien? 
Hvilke medisiner har du gått på siden studien? 
Hvis du ikke fikk kolesterolsenkendemedisin rett etter studien - vet du hvorfor det tok lang tid? 
Bruker du kolesterolsenkende medikamenter på resept idag? 
Hvis ja, type og dosering 
Bruker du naturmedisiner for kolesterolet? 
Når ble kolesterolverdiene dine målt sist? 
Hva er de nyeste kolesterolverdiene dine? (totalkolesterol)? 
Hva er de nyeste kolesterolverdiene dine (HDL)? 
Hva er de nyeste kolesterolverdiene dine? (LDL)? 
Hva er de nyeste kolesterolverdiene dine? (triglyserider)? 
Hva er de nyeste kolesterolverdiene dine (ApoA1)? 
Hva er de nyeste kolesterolverdiene dine (ApoB)? 
Hva er de nyeste kolesterolverdiene dine? Lp(a)? 
Hva er de nyeste kolesterolverdiene dine? ASAT? 
Hva er de nyeste kolesterolverdiene dine? ALAT? 
Med tanke på dette blodrpøvesvaret hvor enig eller uenig er du i påstanden: ''jeg er fornøyd med 
kolesterolverdiene mine''? 
              Helt enig, Delvis enig, Verken uenig eller enig, Delvis uenig, Helt Uenig 
Hvis uenig  hva er grunnen til åt du ikke bruker større dose eller flere medikamenter? 
Siden studien, har du opplevd bivirkninger av kolesterolsenkende medisiner? 
 Hvis ja, av hvilke medisiner? 
 Hvis ja, hvilken type bivirkning? 
Hvis du noen gang har hatt bivirkninger, hvordan har det påvirket din livskvalitet? 
 Hvis ja, hvordan har det påvirket behandlingen din? 
 Hvis ja, hvem har diagnostisert bivirkningene? 
 Hvis ja, har det vært utslag på blodprøver? 
 Hvis ja, hvor enig/uenig  er du i påstanden, "jeg er helt sikker på at bivirkningene har skyldtes 
medisinen og ikke vært vanlige kroppslige plager som kommer fra tid til annen" 
  Helt enig, delvis enig, verken enig eller uenig, delvis uenig, helt uenig 
 Hvis ja, har bivirkningene ført til at du har sluttet med medisinen over en lengere periode 
(over 14 dager)? 
 Hvis ja, hvor lenge? 
 Fører bivirkningene til at du i enkelte situasjoner unnlater å ta den faste kolesterolsenkende 
medisinen? 
 Hvis ja, beskriv i hvilke situasjoner du lar være å ta medisinen 
Glemmer du ofte å ta medisinen? 
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 Hva er som oftest grunnen til at du glemmer å ta den? 
Har du kolesterolavleiringer (xanthomknuter, xanthelasmer, arcus cornea)? 
 Hvordan har disse endret seg siste 10 år (etter studien)? 
Har du hatt hjertesykdom? (hjerteinfarkt, angina, blodpropp) 
 Hjertesykdom årstall, diagnose, tiltak 
Har foreldrene dine hatt hjertesykdom? 
Har du hatt noen andre sykdommer (utenom forkjølelser ol)? 
Hvilke medikamenter (medisiner/naturmediiner utenom kolesterolsenkende) bruker du i dag? 
Er du student, i jobb, eller ikke i jobb? 
Hvor mange år høyere utdanning etter VGS har du? (inkluder hvor mange år du får når du er ferdig 
med studiet) 
Kosthold: forteller dem hva de scoret på Smart Diet og svarer på spørsmål 
Når var sist gang du fikk kostholdveiledning? 
Hvor mange timer i uka trener du utholdenhet? 
Hvor mange timer i uka trener du styrke? 
Røyker du, eller har du noen gang gjort det? 
 Hvor mange røyker du/røykte du om dagen?  
 Når startet/og sluttet du? 
Snuser du? 
 Hvor lenge har du brukt snus? 
Antall alkoholenheter i uka 
”Jeg tror at sunn kost og livsstil er minst like viktig som å ta riktig medisin med tanke på FH” 
 Helt enig, Delvis enig, Verken enig eller uenig, Delvis uenig, Helt uenig 
”Jeg spiser sunnere enn jeg ville gjort om jeg ikke hadde FH” 
”Jeg synes det er vanskelig å finne kolesterolvennlig mat på offentlige spisesteder” 
”Jeg synes det kan skape vanskelige situasjoner når jeg blir servert mat jeg vet ikke er bra for meg i 
sosiale sammenhenger” 
”Jeg føler at FH forringer min matglede” 
”Jeg trener/mosjonerer mer enn jeg ville gjort om jeg ikke hadde FH” 
”Jeg røyker ikke/sluttet å røyke/røyker mindre pga jeg har FH” 
”Jeg skulle ønske jeg slapp å bekymre meg om livsstilen min (pga FH)” 
”Jeg føler at jeg burde vært flinkere til å leve sunt” 
”Jeg er glad for at jeg er bevisst på å leve sunt” 
Anser du din helse som bedre enn gjennomsnittet, gjennomsnittlig, dårligere enn gjennomsnittet? 
 Bedre enn gjennomsnittet, gjennomsnittlig, dårligere enn gjennomsnittet 
 Hvis bedre, hvorfor? 
 Hvis dårligere, hvorfor? 
”Jeg bekymrer meg over om jeg kommer til å få hjerteinfarkt (hjertesykdom) pga FH” 
 Helt enig, Delvis enig, Verken enig eller uenig, Delvis uenig, Helt uenig 
”Jeg stoler på at behandlingen min kommer til å forhindre at jeg får hjerteinfarkt (hjertesykdom)” 
”Jeg er redd for at den av foreldrene mine som har FH kommer til å bli hjertesyk (igjen)?” 
”Jeg er engstelig over tanken på at jeg kan gi (eller har gitt) FH videre til mine barn” 
”Det å ha FH har aldri vært noe problem å snakke om I min familie” 
”Jeg synes det er vanskelig å fortelle andre om at jeg har FH” 
”Jeg skulle ønske at jeg og min familie ikke visste om FH diagnosen” 
”Jeg skulle ønske at jeg hadde fått diagnosen om FH senere (som voksen)” 
Er det ting i oppfølgningen din som kunne gjort det lettere å leve med FH, hvis så hva da? 
Hvor enig/uenig er du I påstanden "jeg er fornøyd med min oppfølgning av FH" 
 Helt enig, Delvis enig, Verken enig eller uenig, Delvis uenig, Helt uenig 
Hva er du mest fornøyd med i din oppfølgning? 
Hva er du minst fornøyd med i din oppfølgning? 
”Jeg gruer meg til legekonsultasjonene når det gjelder FH” 
 Helt enig, Delvis enig, Verken enig eller uenig, Delvis uenig, Helt uenig 
Hvis ikke Helt Uenig, hvorfor? 
”Jeg føler ikke at helsevesenet bør være så pågående når det gjelder FH” 
 Helt enig, Delvis enig, Verken enig eller uenig, Delvis uenig, Helt uenig 
”Jeg ønsker blodprøvekontroll og legeundersøkelse for FH med følgende hyppighet” 
 4 ganger årlig, 2 ganger årlig, 1 gang I året, sjeldnere 
”Jeg føler ikke at jeg får den informasjonen jeg trenger om FH” 
 Helt enig, Delvis enig, Verken enig eller uenig, Delvis uenig, Helt uenig 
  
88  
”Jeg føler at det jeg leser/hører om i media stemmer godt overens med det legen min og LK har fortalt 
meg om kolesterol og kolesterolsenkende medisiner” 
 Helt enig, Delvis enig, Verken enig eller uenig, Delvis uenig, Helt uenig 
”Det hender at medieoppslag gjør meg skeptisk til råd jeg har fått av legen min eller LK  om FH 
behandlingen min” 
”Jeg er usikker på hvilke kilder til informasjon om FH jeg kan stole på” 
Hva er dine kilder til det du kan om FH? 
Informasjon fra studien 
 kryss av hvis relevant 
 Lærte av foreldre som barn 
 Informasjon fra å komme til LK 
 Informasjon fra fastlegen 
 FH-foreningen 
 Andre kilder 
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Appendix 7: Participation the parent studies  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are given as n (%) 
1  n indicates number of individuals  
  
Parent trial(s) participated in n 1 (%) 
Akid 
Zink 
Plantesterol 
15 (22.4%) 
13 (19.4%) 
13 (19.4%) 
Ezi-Simva 3 (4.5%) 
Welchol 4 (6.0%) 
PLUTO 11 (16.4%) 
Plantesterol + PLUTO 3 (4.5%) 
Plantesterol + Ezi-Simva 1 (1.5%) 
Ezi-Simva + PLUTO 1 (1.5%) 
PLUTO + Welchol  2 (3.0%)  
Plantesterol + PLUTO + Ezi-Simva 1 (1.5%) 
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Appendix 8: Subjective evaluation of parent study participation  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are given in n (valid percent) 
1 n indicates number of individuals  
 
 
 
 
 
 
 
 
 
  
Characteristics  n 1 (%) 
Who decided study participation?  
Myself 17 (25.8%) 
Parents decided, I agreed 48 (72.7%) 
Parents decided, I did not agree 1 (1.5%) 
Why did you participate?   
To get better treatment and follow-up  36 (54.5%) 
Doctors recommendation  3 (4.5%) 
To find a drug I can tolerate  4 (6.1%) 
Help with science  11 (16.7%) 
Exiting to be involved in a project  2 (3.0%) 
To get better treatment and follow up 
and help with science 
9 (13.6%) 
Do not  know  1 (1.5%) 
Did you find it stressful to participate in the 
study as a child?  
 
Agree fully 1 (1.5%) 
Agree partly 7 (10.6%) 
Neither agree or disagree  3 (4.5%) 
Disagree partly 13 (19.7%) 
Disagree fully  42 (63.6%) 
Did you find it positive to have been included 
in a study?   
 
Agree fully 56 (86.2%) 
Agree partly 3 (4.6%) 
Neither agree or disagree  5 (7.7%) 
Disagree partly 1 (1.5%) 
Disagree fully  0 (0%) 
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Subjective experiences of being included in the parent study/studies   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are given in n (valid percent) 
1 n indicates number of individuals  
N/A = not applicable  
 
 
Characteristics  n 1(%) 
 
Did you get something positively out of being involved in the study?   
No  20 (30.8%) 
Yes 45 (69.2%) 
If yes, what   
N/A 20 (30.8%) 
Frequently and close follow-up  7 (10.8%) 
Increased knowledge / understanding of the disease 5 (7.7%) 
Better cholesterol levels 4 (6.2%) 
Dietary advices  8 (12.3%) 
Travelling to Oslo 2 (3.1%) 
Involved in testing a new medication 3 (4.6%) 
Follow-up and increased knowledge  4 (6.2%) 
Dietary advices and increased knowledge about the disease 6 (9.2%) 
Dietary advices and travelling to Oslo 1 (1.5%) 
Dietary advices and follow-up  3 (4.6%) 
Generally positive 2 (3.1%) 
Did you get something negatively out of being involved in the study?   
No 59 (90.8%) 
Yes  6 (9.2%) 
If yes, what  
N/A 59 (90.8%) 
Side effects of the medication  1 (1.5%) 
“Fasting period” 1 (1.5%) 
Blood samples uncomfortable  2 (3.0%) 
Blood samples uncomfortable and dietary advices  1 (1.5%) 
Blood samples uncomfortable and side effects  1 (1.5%) 
